[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 538
1. Combs SE, Thilmann C, Debus J, Schulz-Ertner D: Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas.
  • PURPOSE: To evaluate the effectiveness and long-term outcome of stereotactic radiosurgery (SRS) for acoustic neuromas (AN).
  • Two patients suffered from neurofibromatosis type 2.
  • [MeSH-major] Hearing / radiation effects. Neuroma, Acoustic / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Facial Nerve / radiation effects. Facial Paralysis / etiology. Female. Hearing Loss / etiology. Humans. Male. Middle Aged. Neurofibromatosis 2 / complications. Radiation Injuries / etiology. Trigeminal Neuralgia / etiology

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16464537.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Roche PH, Bouvier C, Chinot O, Figarella-Branger D: Genesis and biology of vestibular schwannomas. Prog Neurol Surg; 2008;21:24-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genesis and biology of vestibular schwannomas.
  • This review chapter is a synthesis of the recent literature about pathogenesis of schwannomas with emphasis on vestibular schwannomas (VSs).
  • The understanding of this mechanism has been gained from molecular genetic studies of neurofibromatosis type 2 (NF2) patients, in whom mutations of a tumor suppressor gene (NF2 gene) was clearly identified.
  • S/M is the normal NF2 gene product.
  • Lack of normal S/M protein in the schwannoma cell is due to gene mutation in 50% of sporadic VSs.
  • Apart from the involvement of the S/M pathway, the authors review the potential role of other genetic abnormalities and growing factors that are supposed to be involved in the pathogenesis of vs. Understanding the pathways of action and regulation of S/M may provide the basics for identifying potential therapeutic targets, which is of paramount importance for a better management of NF2 patients.
  • [MeSH-major] Genes, Neurofibromatosis 2 / physiology. Neurofibromin 2 / physiology. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology
  • [MeSH-minor] Epigenesis, Genetic / physiology. Humans. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / genetics

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810196.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neurofibromin 2
  • [Number-of-references] 43
  •  go-up   go-down


3. Hasegawa T, Fujitani S, Katsumata S, Kida Y, Yoshimoto M, Koike J: Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years. Neurosurgery; 2005 Aug;57(2):257-65; discussion 257-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for vestibular schwannomas: analysis of 317 patients followed more than 5 years.
  • OBJECTIVE: Many investigators have reported successful treatment of vestibular schwannomas with gamma knife radiosurgery (GKRS).
  • However, long-term outcomes should be evaluated before concluding that GKRS is truly safe and effective for the treatment of vestibular schwannomas.
  • METHODS: Between May 1991 and December 1998, 346 consecutive patients (excluding those presenting with neurofibromatosis Type 2) were treated with GKRS.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Neuroma, Acoustic / surgery. Radiosurgery / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094154.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Sharma MS, Singh R, Kale SS, Agrawal D, Sharma BS, Mahapatra AK: Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. J Neurooncol; 2010 Jun;98(2):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2.
  • To analyze the effect of Gamma Knife radiosurgery (GKS) on tumor control and hearing preservation rates in patients with vestibular schwannomas (VS) in a setting of neurofibromatosis type 2 (NF 2), a retrospective study was carried out at a tertiary-level referral Gamma Knife unit.
  • Dose plans, pre- and postoperative radiology, and follow-up clinical records of patients with NF 2 who had undergone GKS for VS using a Leksell Gamma Knife (Elekta Instruments AB, Stockholm, Sweden) model B unit from 1997 to 2008 were reviewed.
  • Twenty-four patients had bilateral vs. The commonest clinical presentation was hearing loss and tinnitus.
  • GKS for VS provides satisfactory tumor control and hearing preservation in patients with NF 2.
  • [MeSH-major] Hearing / physiology. Neurofibromatosis 2 / surgery. Radiosurgery / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ASHA. 1981 Jul;23(7):493-500 [7052898.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):195-199 [28306432.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):696-705; discussion 705-6 [9092842.001]
  • [Cites] Neurochirurgie. 2000 Sep;46(4):339-53; discussion 354 [11015671.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):383-89; discussion 389-90 [10825525.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):447-53 [17704364.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):390-8 [19109818.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Neurosurgery. 2007 Mar;60(3):460-8; discussion 468-70 [17327790.001]
  • [Cites] Neurosurgery. 2005 Aug;57(2):257-65; discussion 257-65 [16094154.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] No Shinkei Geka. 1995 Feb;23(2):131-5 [7877733.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Neurosurgery. 2006 Jul;59(1):77-85; discussion 77-85 [16823303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):845-51 [17379451.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1288-93 [12933938.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1450-9 [14630285.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • (PMID = 20405305.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Niv MY, Iida K, Zheng R, Horiguchi A, Shen R, Nanus DM: Rational redesign of neutral endopeptidase binding to merlin and moesin proteins. Protein Sci; 2009 May;18(5):1042-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that the ERM-related protein merlin (NF2) does not bind NEP or its cytosolic region.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Apr 28;101(3):259-70 [10847681.001]
  • [Cites] Biopolymers. 2009 Jul;91(7):505-13 [19226619.001]
  • [Cites] J Clin Neurosci. 2001 Jan;8(1):4-7 [11148074.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1425-36 [11163215.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] J Cell Sci. 2002 Nov 1;115(Pt 21):3991-4000 [12356905.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):502-14 [12554651.001]
  • [Cites] Biochem Soc Trans. 2003 Jun;31(Pt 3):723-7 [12773192.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3249-54 [12947059.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1242-55 [14570903.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):67-78 [14749127.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11898-905 [14704146.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W526-31 [15215442.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4096-100 [15217945.001]
  • [Cites] J Neurochem. 1984 Nov;43(5):1295-301 [6387047.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 25;18(22):6485-9 [2251111.001]
  • [Cites] Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):663-8 [8224486.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] Gene. 1997 Oct 24;200(1-2):135-44 [9373147.001]
  • [Cites] Nat Med. 1998 Jan;4(1):50-7 [9427606.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12517-22 [15699051.001]
  • [Cites] Proteins. 2005 Aug 1;60(2):232-8 [15981252.001]
  • [Cites] Biochim Biophys Acta. 2005 Aug 1;1751(1):52-9 [16054017.001]
  • [Cites] J Am Chem Soc. 2005 Oct 12;127(40):14072-9 [16201829.001]
  • [Cites] Biotechniques. 2005 Oct;39(4):575-6 [16235571.001]
  • [Cites] Nucleic Acids Res. 2006;34(17):e112 [16971460.001]
  • [Cites] J Comput Aided Mol Des. 2006 Jul-Aug;20(7-8):437-48 [17103019.001]
  • [Cites] PLoS Comput Biol. 2006 Nov 10;2(11):e153 [17096593.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1446-59 [17134719.001]
  • [Cites] Folia Histochem Cytobiol. 2006;44(4):231-48 [17219717.001]
  • [Cites] Curr Opin Cell Biol. 2007 Feb;19(1):51-6 [17175152.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):222-9 [17442573.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19854-62 [17459884.001]
  • [Cites] Proteins. 2007 Dec 1;69(4):839-44 [17803236.001]
  • [Cites] Genes Cells. 2007 Dec;12(12):1329-38 [18076570.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1001-9 [18075579.001]
  • [Cites] J Comb Chem. 2008 Mar-Apr;10(2):256-66 [18271560.001]
  • [Cites] Mol Pharmacol. 2008 May;73(5):1578-86 [18314496.001]
  • [Cites] Diabetes Metab Res Rev. 2008 Oct;24(7):577-84 [18613220.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29602-12 [18753140.001]
  • [Cites] J Clin Invest. 2000 Dec;106(11):1399-407 [11104793.001]
  • (PMID = 19388049.001).
  • [ISSN] 1469-896X
  • [Journal-full-title] Protein science : a publication of the Protein Society
  • [ISO-abbreviation] Protein Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA80240; United States / NCI NIH HHS / PC / PC040758
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Neurofibromin 2; 0 / Peptides; 144131-77-1 / moesin; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC2771306
  •  go-up   go-down


6. Thomas R, Duke SE, Wang HJ, Breen TE, Higgins RJ, Linder KE, Ellis P, Langford CF, Dickinson PJ, Olby NJ, Breen M: 'Putting our heads together': insights into genomic conservation between human and canine intracranial tumors. J Neurooncol; 2009 Sep;94(3):333-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, however, genomic imbalances orthologous to some of the hallmark aberrations of human intracranial tumors, including chromosome 22/NF2 deletions in meningiomas and chromosome 1p/19q deletions in oligodendrogliomas, were not major events in the dog.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):440-53 [10640979.001]
  • [Cites] Cytogenet Genome Res. 2008;122(2):110-21 [19096206.001]
  • [Cites] Vet Pathol. 2000 Mar;37(2):160-7 [10714645.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Genome Res. 2002 Jun;12(6):996-1006 [12045153.001]
  • [Cites] J Small Anim Pract. 2002 Jun;43(6):240-6 [12074288.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):147-59 [12127399.001]
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1530-7 [14562028.001]
  • [Cites] Vet Pathol. 2003 Nov;40(6):659-69 [14608019.001]
  • [Cites] Vet Pathol. 2004 Jan;41(1):10-9 [14715963.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Jun;75 Suppl 2:ii2-11 [15146033.001]
  • [Cites] Science. 2004 May 21;304(5674):1160-4 [15155949.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):210-8 [15309910.001]
  • [Cites] BMC Genomics. 2004 Sep 13;5:65 [15363096.001]
  • [Cites] Hereditas. 1972;71(1):163-8 [4142025.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):2090-1 [2230902.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Chromosome Res. 1999;7(5):401-6 [10515215.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3636-7 [15201182.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Apr;64(4):312-22 [15835267.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2253-7 [15980208.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5654-61 [15994938.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Vet Pathol. 2005 Sep;42(5):550-8 [16145201.001]
  • [Cites] Genome Res. 2005 Dec;15(12):1831-7 [16339382.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):803-19 [16341006.001]
  • [Cites] J Vet Intern Med. 2006 May-Jun;20(3):669-75 [16734106.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):995-1006 [16897744.001]
  • [Cites] Mol Cancer. 2006;5:39 [17002787.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):327-35 [17243164.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2368-76 [17285580.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4541-4 [17510377.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1219-30 [17161458.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):245-58 [17522335.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Oct;46(10):875-94 [17620294.001]
  • [Cites] J Hered. 2007;98(5):474-84 [17702974.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):133-48 [17874037.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1416-24 [17940511.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 [18077431.001]
  • [Cites] Lancet Neurol. 2008 Jan;7(1):14-6 [18093552.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):803-10 [17667943.001]
  • [Cites] Chromosome Res. 2008;16(1):145-54 [18293109.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Cytogenet Genome Res. 2008;120(1-2):50-60 [18467825.001]
  • [Cites] J Vet Intern Med. 2008 May-Jun;22(3):586-95 [18466258.001]
  • [Cites] Clin Neurosurg. 2007;54:4-9 [18504889.001]
  • [Cites] J Neurooncol. 2008 Jul;88(3):293-8 [18345516.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • (PMID = 19333554.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS051190-01; United States / NINDS NIH HHS / NS / R21 NS051190; United States / NINDS NIH HHS / NS / R21 NS051190-01; United States / NINDS NIH HHS / NS / NS051190; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS183408; NLM/ PMC3225023
  •  go-up   go-down


7. McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, Magendantz M, Jacks T: The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A; 2007 Feb 27;104(9):3261-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.
  • We found that in the mouse embryo, expression of the Nf2 tumor suppressor, merlin, is dynamically regulated during tissue fusion: Nf2 expression is low at the leading front before fusion and high across the fused tissue bridge.
  • Mosaic Nf2 mutants exhibit a global defect in tissue fusion characterized by ectopic detachment and increased detachment-induced apoptosis (anoikis).
  • Our work reveals that regulation of Nf2 expression is a previously unrecognized means of controlling adhesion at the leading front, thereby ensuring successful tissue fusion.

  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • eagle-i research resources. PMID 17360635 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Dec 1;13(23):3136-48 [10601039.001]
  • [Cites] Nat Cell Biol. 2004 Jan;6(1):21-30 [14647292.001]
  • [Cites] Dev Biol. 2000 Jun 15;222(2):296-306 [10837119.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 May 7;53(17):362-5 [15129193.001]
  • [Cites] Arch Ophthalmol. 2004 Jul;122(7):1002-11 [15249365.001]
  • [Cites] Z Zellforsch Mikrosk Anat. 1971;115(2):226-64 [4102323.001]
  • [Cites] Anat Rec. 1977 Dec;189(4):625-40 [596653.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Methods Enzymol. 1993;225:361-73 [8231863.001]
  • [Cites] J Anat. 1993 Aug;183 ( Pt 1):121-9 [8270467.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):185-92 [8162073.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):664-79 [8954735.001]
  • [Cites] Curr Biol. 1997 Apr 1;7(4):281-4 [9094312.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1253-65 [9171370.001]
  • [Cites] Mol Cell Neurosci. 1998 Jul;11(4):183-93 [9675050.001]
  • [Cites] Cell. 1999 Jul 23;98(2):147-57 [10428027.001]
  • [Cites] Dev Dyn. 2005 Jun;233(2):528-39 [15844200.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12843-8 [16126904.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] Dev Biol. 2006 Jul 15;295(2):647-63 [16712836.001]
  • [Cites] Dev Dyn. 2006 Oct;235(10):2771-85 [16894610.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1225-37 [17090534.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Neurosci. 2001 Feb 1;21(3):788-97 [11157065.001]
  • [Cites] Genomics. 2002 Jan;79(1):63-76 [11827459.001]
  • [Cites] Neurology. 2002 Jun 25;58(12):1849-52 [12084890.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):354-62 [12118253.001]
  • [Cites] Dev Cell. 2002 Aug;3(2):259-70 [12194856.001]
  • [Cites] Curr Opin Cell Biol. 2002 Oct;14(5):569-74 [12231351.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):752-5 [12591720.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Mar;4(3):225-36 [12612641.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Nat Rev Genet. 2003 Oct;4(10):784-93 [13679871.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Dev Biol. 2000 Apr 15;220(2):343-57 [10753521.001]
  • (PMID = 17360635.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neurofibromin 2
  • [Other-IDs] NLM/ PMC1801999
  •  go-up   go-down


8. Barski D, Wolter M, Reifenberger G, Riemenschneider MJ: Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol; 2010 May;20(3):623-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed direct sodium bisulfite sequencing in a series of 50 meningiomas, including 27 benign meningiomas [World Health Organization (WHO) grade I], 11 atypical meningiomas (WHO grade II) and 12 anaplastic meningiomas (WHO grade III), and found hypermethylation of TIMP3 in 67% of anaplastic meningiomas, but only 22% of atypical and 17% of benign meningiomas.
  • TIMP3 is located in the chromosomal band 22q12, the allelic loss of which occurs early in meningioma tumorigenesis and preferentially targets the NF2 tumor suppressor gene.
  • Thus, TIMP3 inactivation by methylation seems fairly exclusive to meningiomas with allelic losses on 22q12 but--in contrast to NF2 mutation--appears to be involved in meningioma progression as it is associated with a more aggressive, high-grade meningioma phenotype.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Disease Progression. Down-Regulation / genetics. Humans. Male. Middle Aged

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19922547.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / TIMP3 protein, human; 0 / Tissue Inhibitor of Metalloproteinase-3
  •  go-up   go-down


9. Nascimento AF, Fletcher CD: The controversial nosology of benign nerve sheath tumors: neurofilament protein staining demonstrates intratumoral axons in many sporadic schwannomas. Am J Surg Pathol; 2007 Sep;31(9):1363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This concept has recently been disputed in cases associated with neurofibromatosis type 2.
  • The amount (rare, focal, multifocal, and diffuse) and distribution (central and/or peripheral) of axons within the tumors were analyzed.
  • NFP-positive axons were identified in 11 of 20 (55%) conventional schwannomas (2 rare, 4 focal, 3 multifocal, and 2 diffuse; 5 central, 4 peripheral, and 2 central and peripheral) and in 15 of 20 (75%) cellular schwannomas (3 rare, 6 focal, and 6 multifocal; 12 central, 1 peripheral, and 2 central and peripheral).
  • Of the 20 ancient schwannomas, 7 cases (35%) showed intratumoral axons, highlighted by NFP immunostaining (1 rare, 4 focal, 1 multifocal, and 1 diffuse; 4 peripheral, 2 central, and 1 central and peripheral).
  • Most cases of gastric schwannoma showed no evidence of intratumoral axons; 9 cases (90%) were negative for NFP and only 1 case (10%) was positive (focal and central).
  • Seven of 10 cases (70%) of plexiform schwannomas were negative for NFP, whereas only 3 cases (30%) showed positive axons (2 multifocal and 1 focal; 3 central).
  • Although NFP-positive axons were most often present in the conventional and cellular variants of schwannoma, their presence was also observed in a minority of ancient, gastric and plexiform schwannomas.
  • Differentiation between neurofibroma and schwannoma in cases with overlapping cytoarchitectural features should not be based solely on the presence or absence of NFP-positive axons within a given tumor.
  • [MeSH-major] Axons / chemistry. Neurilemmoma / diagnosis. Neurofibroma / diagnosis. Neurofilament Proteins / analysis. S100 Proteins / analysis. Schwann Cells / chemistry. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Cell Differentiation. Cell Proliferation. Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Invasiveness. Predictive Value of Tests. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721192.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofilament Proteins; 0 / S100 Proteins
  •  go-up   go-down


10. Miyakawa T, Kamada N, Kobayashi T, Hirano K, Fujii K, Sasahara Y, Nagai Y, Shinkai H: Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom. J Dermatol; 2007 Jan;34(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
  • Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder that is caused by inactivating mutations or a loss of both alleles in the NF2 tumor-suppressor gene.
  • Bilateral vestibular schwannomas are considered to be the hallmark of this disease, with hearing loss and tinnitus which are caused by these tumors, usually presenting as the initial symptoms.
  • In addition to other tumors and ocular findings, skin abnormalities also occur in NF2, however, they are not so characteristic as neurofibromatosis type 1 (NF1).
  • We herein report a case of NF2 which occurred in a 5-year-old boy.
  • He had multiple cutaneous tumors but did not have any symptoms related to vestibular schwannomas.
  • A histopathological examination revealed these tumors to be plexiform schwannomas; we therefore suspected NF2.
  • As a result of magnetic resonance imaging with gadolinium enhancement, bilateral vestibular schwannomas were detected and a final diagnosis of NF2 was thus made.
  • The association between NF2 and multiple depigmented spots is unknown, we therefore consider that multiple cutaneous plexiform schwannomas may strongly suggest an association with NF2.
  • [MeSH-major] Neurilemmoma / pathology. Neurofibromatosis 2 / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Humans. Male. Neuroma, Acoustic / pathology


11. Kuo YH, Roos D, Brophy BP: Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2. J Clin Neurosci; 2008 Jul;15(7):744-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear accelerator radiosurgery for treatment of vestibular schwannomas in neurofibromatosis 2.
  • Management of vestibular schwannomas in patients with neurofibromatosis 2 (NF2) balances growth control against preservation of hearing with the primary aim of maintaining patient quality of life.
  • Previous studies on the efficacy of stereotactic radiosurgery for vestibular schwannomas in NF2 have reported results from delivery by Gamma Knife systems.
  • Modelling studies suggest that lesional conformality is superior with Gamma Knife, but clinical studies on sporadic vestibular schwannomas show equivalent results between the two systems.
  • Our experience with LINAC radiosurgery in NF2 reported here shows good long-term growth control in four patients with vestibular schwannomas.
  • [MeSH-major] Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery. Radiosurgery / statistics & numerical data
  • [MeSH-minor] Adult. Brain Stem / pathology. Brain Stem / physiopathology. Brain Stem / surgery. Deafness / etiology. Deafness / physiopathology. Female. Humans. Magnetic Resonance Imaging. Male. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Retrospective Studies. Treatment Outcome. Vestibular Nerve / pathology. Vestibular Nerve / physiopathology. Vestibular Nerve / radiation effects

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403208.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


12. Buccoliero AM, Castiglione F, R Degl'Innocenti D, Gheri CF, Garbini F, Taddei A, Ammannati F, Mennonna P, Taddei GL: NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study. Neuropathology; 2007 Feb;27(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-pCR study.
  • One of the most common regions involved in the meningiomas tumorigenesis is chromosome 22q where the NF2 gene resides.
  • The deficiency or loss of the NF2 gene product, merlin/schwannomin, plays a role in tumor development and metastatization.
  • Several studies have indicated NF2 gene inactivation as an early tumorigenic event unrelated to the histological grade or clinical behavior.
  • On the contrary, the NF2 gene alteration rate differs between the different histotypes.
  • A pathogenesis independent from the NF2 gene has been suggested in meningothelial meningiomas.
  • In the present work, we studied the NF2 gene expression through real time-PCR (RT-PCR) in 30 meningiomas.
  • The average of the NF2 gene expression of all meningiomas was considered as reference value.
  • The average of expression of WHO grade I and II meningiomas was higher than the average of all meningiomas, whereas that of WHO grade III meningiomas was lower.
  • When we compared the NF2 gene expression in the different meningioma grades we did not note a significant difference (P = 0.698) despite the tendency to decrease from grade I to grade III.
  • The difference in NF2 gene expression between meningothelial and non-meningothelial meningiomas was statistically significant (P = 0.013).
  • Our data supports the finding that alterations in NF2 gene alteration are histotype related but not grade related.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319281.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


13. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature; 2010 Jan 21;463(7279):360-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, NF2 mutations were found in non-VHL mutated ccRCC, and several other probable cancer genes were identified.
  • These results indicate that substantial genetic heterogeneity exists in a cancer type dominated by mutations in a single gene, and that systematic screens will be key to fully determining the somatic genetic architecture of cancer.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Genes, Neurofibromatosis 2. Histone-Lysine N-Methyltransferase / genetics. Histones / metabolism. Kidney Neoplasms / genetics. Nuclear Proteins / genetics. Oxidoreductases, N-Demethylating / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2007 Apr;11(4):335-47 [17418410.001]
  • [Cites] Cell. 2007 Mar 23;128(6):1077-88 [17320160.001]
  • [Cites] Cancer Cell. 2007 May;11(5):407-20 [17482131.001]
  • [Cites] Bioinformatics. 2007 Jul 1;23(13):1689-91 [17485433.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2007;8:37-55 [17887919.001]
  • [Cites] Science. 2007 Oct 19;318(5849):447-50 [17761849.001]
  • [Cites] Oncogene. 2007 Dec 10;26(56):7792-8 [18066092.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):361-9 [18297059.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16484-9 [18948595.001]
  • [Cites] Lancet. 2009 Mar 28;373(9669):1119-32 [19269025.001]
  • [Cites] Nat Genet. 2009 May;41(5):521-3 [19330029.001]
  • [Cites] Cancer Cell. 2002 Jun;1(5):459-68 [12124175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11492-7 [16061792.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11486-91 [16081543.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35261-71 [16118227.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2000-11 [16488999.001]
  • [Cites] Genetics. 2006 Aug;173(4):2187-98 [16783027.001]
  • [Cites] PLoS Med. 2006 Mar;3(3):e47 [16417408.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1889-903 [17178841.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):394-404 [17450177.001]
  • [CommentIn] Future Oncol. 2010 Jun;6(6):897-900 [20528227.001]
  • (PMID = 20054297.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE17895
  • [Grant] United Kingdom / Wellcome Trust / / 077012/Z/05/Z; United Kingdom / Wellcome Trust / / 082359; United Kingdom / Wellcome Trust / / 088340; United Kingdom / Wellcome Trust / / 093867; United Kingdom / Wellcome Trust / / 077012
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin; 0 / Histones; 0 / Nuclear Proteins; EC 1.14.11.- / Histone Demethylases; EC 1.14.11.- / KDM5C protein, human; EC 1.14.11.- / UTX protein, human; EC 1.5.- / Oxidoreductases, N-Demethylating; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / Set2 protein, human
  • [Other-IDs] NLM/ PMC2820242; NLM/ UKMS28099
  •  go-up   go-down


14. Hennigan RF, Foster LA, Chaiken MF, Mani T, Gomes MM, Herr AB, Ip W: Fluorescence resonance energy transfer analysis of merlin conformational changes. Mol Cell Biol; 2010 Jan;30(1):54-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis type 2 is an inherited autosomal disorder caused by biallelic inactivation of the NF2 tumor suppressor gene.
  • The NF2 gene encodes a 70-kDa protein, merlin, which is a member of the ezrin-radixin-moesin (ERM) family.
  • Using these tools, we find that merlin exists predominately as a monomer in a stable, closed conformation that is mediated by the central alpha-helical domain.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Structure. 2006 Apr;14(4):777-89 [16615918.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):445-9 [14990965.001]
  • [Cites] J Mol Biol. 2007 Feb 2;365(5):1446-59 [17134719.001]
  • [Cites] Trends Biochem Sci. 2007 Sep;32(9):407-14 [17764955.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C874-84 [17553936.001]
  • [Cites] Methods Cell Biol. 2008;85:381-93 [18155471.001]
  • [Cites] Biochemistry. 1998 Jan 6;37(1):33-40 [9425023.001]
  • [Cites] J Cell Biol. 1998 Feb 9;140(3):647-57 [9456324.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] Biochim Biophys Acta. 1998 Sep 8;1387(1-2):1-16 [9748471.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Biotechniques. 1999 Aug;27(2):368-75 [10457846.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8447-54 [15378014.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1242-54 [15788482.001]
  • [Cites] Appl Biochem Biotechnol. 2005 Aug;126(2):149-56 [16118468.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29602-12 [18753140.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4043-51 [19351837.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34438-42 [10567424.001]
  • [Cites] Biophys J. 2000 Mar;78(3):1606-19 [10692345.001]
  • [Cites] Cell. 2000 Apr 28;101(3):259-70 [10847681.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4449-62 [10970839.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:113-43 [11031232.001]
  • [Cites] J Cell Biol. 2000 Nov 27;151(5):1067-80 [11086008.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7621-9 [11106646.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2723-41 [11387207.001]
  • [Cites] J Mol Biol. 2001 Jul 27;310(5):973-8 [11502006.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Methods Mol Biol. 1997;63:305-24 [9113659.001]
  • [Cites] J Mol Biol. 1997 Apr 11;267(4):1039-52 [9135129.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1253-65 [9171370.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):87-90 [11753368.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 Mar;58(Pt 3):381-91 [11856822.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] J Cell Sci. 2002 Jun 15;115(Pt 12):2569-80 [12045227.001]
  • [Cites] J Mol Biol. 2002 May 3;318(3):901-10 [12054832.001]
  • [Cites] Mol Cells. 2002 Aug 31;14(1):108-14 [12243339.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):177-9 [12499563.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):502-14 [12554651.001]
  • [Cites] Biochemistry. 2003 Oct 14;42(40):11634-41 [14529273.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):580-7 [14724586.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):653-9 [14993232.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • (PMID = 19884346.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078524; United States / NCI NIH HHS / CA / R01-CA78524
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / Phosphoproteins; 0 / Sodium-Hydrogen Antiporter; 0 / sodium-hydrogen exchanger regulatory factor
  • [Other-IDs] NLM/ PMC2798298
  •  go-up   go-down


15. Sakai T, Vallejo MC, Shannon KT: A parturient with neurofibromatosis type 2: anesthetic and obstetric considerations for delivery. Int J Obstet Anesth; 2005 Oct;14(4):332-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A parturient with neurofibromatosis type 2: anesthetic and obstetric considerations for delivery.
  • Neurofibromatosis type 2 is an extremely rare form of neurofibromatosis characterized by central nervous system involvement with bilateral vestibular schwannomas and spinal tumors.
  • Anesthetic management of a parturient with neurofibromatosis type 2 has not been fully reported, and the condition is challenging to obstetric anesthesiologists due to the presence of intracranial and intraspinal canal neurofibromas.
  • We present a case of neurofibromatosis type 2 referred for delivery.
  • Because of central neuraxial involvement, regional anesthesia was avoided, and the patient delivered by cesarean section under general anesthesia.
  • The importance of pre-operative diagnosis and multidisciplinary management for neurofibromatosis type 2 is emphasized and anesthetic and obstetric considerations for delivery are presented.
  • [MeSH-major] Anesthesia, General. Anesthesia, Obstetrical. Central Nervous System Neoplasms. Cesarean Section. Neurofibromatosis 2. Pregnancy Complications, Neoplastic


16. Plouin PF, Gimenez-Roqueplo AP: Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab; 2006 Sep;20(3):421-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phaeochromocytomas and paragangliomas may be sporadic or the result of several genetic diseases: multiple endocrine neoplasia type 2, neurofibromatosis 1, von Hippel-Lindau disease, succinate dehydrogenase-phaeochromocytoma-paraganglioma syndrome.
  • Familial cases are diagnosed earlier and are more frequently bilateral and recurrent than sporadic cases.
  • Patients should be followed up indefinitely, particularly if they have familial or extra-adrenal tumours.
  • [MeSH-major] Paraganglioma / complications. Paraganglioma / diagnosis. Pheochromocytoma / complications. Pheochromocytoma / diagnosis
  • [MeSH-minor] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / radiography. Adrenal Gland Neoplasms / radionuclide imaging. Aftercare. Algorithms. Diagnostic Imaging. Follow-Up Studies. Humans. Perioperative Care. Prognosis

  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980203.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


17. Mathieu D, Kondziolka D, Flickinger JC, Niranjan A, Williamson R, Martin JJ, Lunsford LD: Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery; 2007 Mar;60(3):460-8; discussion 468-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates.
  • OBJECTIVE: Vestibular schwannomas present significant management challenges in patients with neurofibromatosis Type 2 (NF2).
  • Facial neuropathy occurred in 8% of tumors, trigeminal neuropathy occurred in 4%, and vestibular dysfunction occurred in 4%.
  • CONCLUSION: Stereotactic radiosurgery is a safe and effective management modality for neurofibromatosis Type 2 vestibular schwannomas.
  • [MeSH-major] Hearing Loss, Sensorineural / epidemiology. Hearing Loss, Sensorineural / prevention & control. Neurilemmoma / epidemiology. Neurilemmoma / surgery. Neurofibromatosis 2 / epidemiology. Neurofibromatosis 2 / surgery. Radiosurgery / statistics & numerical data


18. Suárez C, Rodrigo JP, Ferlito A, Cabanillas R, Shaha AR, Rinaldo A: Tumours of familial origin in the head and neck. Oral Oncol; 2006 Nov;42(10):965-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumours of familial origin in the head and neck.
  • Tumours of familial origin are a rare event in the head and neck but despite this, they deserve a growing interest.
  • Familial paragangliomas are most of the time limited to the paraganglionar system, but also may be part of different syndromic associations.
  • Multiple endocrine neoplasias type 1 are characterized by the simultaneous occurrence of at least two of the three main related endocrine tumours: parathyroid, enteropancreatic and anterior pituitary.
  • Multiple endocrine neoplasia type 2 is due to a germline mutation in the RET proto-oncogene.
  • The most central clinical difference with MEN-1 is that the associated cancer can be prevented or cured by early thyroidectomy in mutation carriers.
  • Individuals with neurofibomatosis type 1 present early in life with pigmentary abnormalities, skinfold freckling and iris hamartomas, as result of NF1 gene mutation.
  • Neurofibromatosis 2 is caused by inactivating mutations of the NF2 gene, and is characterized by the development of nervous system tumours (mainly bilateral vestibular schwannomas), ocular abnormalities, and skin tumours.
  • Finally, the high rate of p16 mutations in squamous cell carcinomas and the association of p16 with familial melanoma propose p16 as an ideal candidate gene predisposing to familial squamous cell carcinomas.
  • The elucidation of the cellular processes affected by dysfunction in familial tumours of the head and neck may serve to identify potential targets for future therapeutic interventions.
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Humans. Multiple Endocrine Neoplasia / genetics. Nasopharyngeal Neoplasms / genetics. Neurofibromatoses / genetics. Paraganglioma / genetics

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857415.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 121
  •  go-up   go-down


19. Siddiqui MA, Leslie T, Scott C, Mackenzie J: Eyelid schwannoma in a male adult. Clin Exp Ophthalmol; 2005 Aug;33(4):412-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid schwannoma in a male adult.
  • Solitary lesions can occur sporadically in the general population but multiple neurofibromas are distinctive feature of neurofibromatosis type 1 and bilateral acoustic schwannomas are a feature of neurofibromatosis type 2.
  • Herein, a case of eyelid schwannoma in a 53-year-old man is described.

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033357.001).
  • [ISSN] 1442-6404
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Walter J, Kuhn SA, Brodhun M, Reichart R, Kalff R: Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2. Clin Neurol Neurosurg; 2009 Jun;111(5):454-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary meningioma and neurinoma associated with multiple CNS tumours in a patient with neurofibromatosis type 2.
  • OBJECTIVE: Neurofibromatosis type 2 (NF2) is a common neurocutaneous disorder that exhibits an autosomal dominant inheritance, with a mutation at chromosome 22q12.2.
  • In general, patients present bilateral vestibular schwannomas, meningiomas and neurinomas of the central and peripheral nervous system as well as neurofibromas and gliomas.
  • There is no reported case of pulmonary meningiomas and neurinomas associated with NF2 until now.
  • PATIENT AND METHODS: Here, we present a 16-year-old girl with NF-2 associated to CNS and pulmonary tumours and we discuss the case in the backlight of the literature.
  • RESULTS: The reported patient presented a de novo NF2 germline mutation (R341X) and displayed the Wishart-type of NF-2 since she is 11 years old, with a huge anaplastic biparietal falx meningioma and a tentorium meningioma and a tumour-associated parietal mass as well as hypacusis starting at the infant age of 3 years.
  • CONCLUSION: This rare case extends our knowledge of NF2 and also raises interesting questions about the pathogenesis of meningiomas outside the CNS.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary. Neurofibromatosis 2 / complications
  • [MeSH-minor] Brain / radiography. Brain Edema. Child. Female. Genes, Neurofibromatosis 2 / physiology. Germ-Line Mutation. Humans. Lung / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed


21. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q: Merlin is a potent inhibitor of glioma growth. Cancer Res; 2008 Jul 15;68(14):5733-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis 2 (NF2) is an inherited cancer syndrome in which affected individuals develop nervous system tumors, including schwannomas, meningiomas, and ependymomas.
  • The NF2 protein merlin (or schwannomin) is a member of the Band 4.1 superfamily of proteins, which serve as linkers between transmembrane proteins and the actin cytoskeleton.
  • In addition to mutational inactivation of the NF2 gene in NF2-associated tumors, mutations and loss of merlin expression have also been reported in other types of cancers.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Int J Cancer. 2005 Dec 10;117(5):755-63 [15981204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] Oncogene. 2006 Apr 20;25(17):2452-67 [16314835.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8511-9 [16951163.001]
  • [Cites] Nat Genet. 2006 Oct;38(10):1142-50 [16980976.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2687-700 [17015431.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):615-24 [17083476.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):450-8 [17049657.001]
  • [Cites] Neurology. 2006 Nov 28;67(10):1863-6 [17130425.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):836-50 [16953231.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2103-19 [17210637.001]
  • [Cites] Dev Biol. 2007 Apr 1;304(1):102-15 [17258190.001]
  • [Cites] Brain Dev. 2007 Jun;29(5):273-80 [17071037.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21206-12 [17513297.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Cell Signal. 2008 May;20(5):795-802 [18160255.001]
  • [Cites] Development. 2000 Mar;127(6):1315-24 [10683183.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:113-43 [11031232.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1311-33 [11390353.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):104-9 [11792551.001]
  • [Cites] Oncogene. 2002 Jan 31;21(6):878-89 [11840333.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Apr 1;134(1):1-5 [11996787.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] Cell. 2003 Aug 22;114(4):445-56 [12941273.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Vitam Horm. 2004;67:453-83 [15110190.001]
  • [Cites] EMBO J. 2004 Sep 15;23(18):3677-88 [15343267.001]
  • [Cites] Nat Rev Genet. 2004 Sep;5(9):691-701 [15372092.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):185-92 [8162073.001]
  • [Cites] Gene. 1995 Dec 29;167(1-2):303-6 [8566796.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):177-81 [9988268.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):182-6 [9988269.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1380-5 [15746036.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2076-86 [15688006.001]
  • [Cites] Cell. 2005 Aug 12;122(3):421-34 [16096061.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8679-89 [16204036.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):494-501 [16546963.001]
  • (PMID = 18632626.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1F32CA128335-01A1; United States / NCI NIH HHS / CA / CA135158-02; United States / NCI NIH HHS / CA / R01 CA135158-02; United States / NCI NIH HHS / CA / CA135158-01A1; United States / NCI NIH HHS / CA / F32 CA128335; United States / NCI NIH HHS / CA / R01 CA135158-01A1; United States / NCI NIH HHS / CA / R01 CA135158; United States / NCI NIH HHS / CA / R01 CA150355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / Wnt Proteins
  • [Other-IDs] NLM/ NIHMS147652; NLM/ PMC2778036
  •  go-up   go-down


22. Cotticelli L, Romano M, Russo S, Borrelli M: Neurofibromatosis type 2: a case of ptosis. Graefes Arch Clin Exp Ophthalmol; 2007 Sep;245(9):1393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2: a case of ptosis.
  • BACKGROUND: Neurofibromatosis type 2 (NF2) is a disorder usually diagnosed later in life since the features are subtle in children.
  • The hallmark is bilateral vestibular schwannomas, which may not appear until after the second decade.
  • Here is described a rare case of NF2 associated with a superior rectus muscle paralysis and severe ptosis.
  • CASE REPORT: A 17-year-old patient with NF2 was referred to us with diagnosis of left-eye superior rectus muscle paralysis, with a later onset of unilateral severe ptosis.
  • The patient showed positive familiar history for NF (the father was affected), bilateral involvement of the acoustic nerves (schwannoma), multiple neurofibromas, and bilateral posterior subcapsular lens opacity.
  • Magnetic resonance imaging (MRI) showed bilateral acoustic neuromas in the left temporal region close to the cavernous sinus; since neurological examination and ocular motility problems had remained stationary over time, surgical correction of ptosis and strabismus was suggested.
  • CONCLUSION: Palpebral ptosis has rarely been reported in NF2.
  • [MeSH-major] Blepharoptosis / complications. Neurofibromatosis 2 / complications. Oculomotor Muscles / pathology. Ophthalmoplegia / complications

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • Genetic Alliance. consumer health - Ptosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1993 Oct;77(10):662-72 [8218038.001]
  • [Cites] Curr Opin Neurol. 2003 Feb;16(1):27-33 [12544854.001]
  • [Cites] Br J Ophthalmol. 1986 Oct;70(10):732-6 [3096370.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1996 Jul-Aug;33(4):255-9 [8827563.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Neurology. 2001 May 8;56(9):1222-4 [11342693.001]
  • [Cites] J AAPOS. 2001 Feb;5(1):9-12 [11182665.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):269-71 [16421138.001]
  • [Cites] J Invest Dermatol. 2000 May;114(5):1017-21 [10771486.001]
  • [Cites] Eye (Lond). 1997;11 ( Pt 1):12-8 [9246269.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • (PMID = 17347811.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Dereure O: [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm]. Ann Dermatol Venereol; 2008 Dec;135(12):888-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm].
  • [Transliterated title] Caractérisation moléculaire de SMARCB1 et NF2 dans la schwannomatose familiale et sporadique : un paradigme qui évolue.
  • [MeSH-major] Chromosomal Proteins, Non-Histone. DNA-Binding Proteins. Neurilemmoma / genetics. Neurofibromatosis 2 / genetics. Transcription Factors
  • [MeSH-minor] Animals. Chromosomes, Human, Pair 22 / genetics. Disease Models, Animal. Humans. Mice. Mutation

  • Genetic Alliance. consumer health - Schwannomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084709.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


24. Bosch MM, Mironov A, Killer HE: Atypical manifestation of neurofibromatosis type 2 in a boy. Eye (Lond); 2005 Jun;19(6):705-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical manifestation of neurofibromatosis type 2 in a boy.
  • [MeSH-major] Cataract / diagnosis. Cranial Nerve Neoplasms / diagnosis. Neurilemmoma / diagnosis. Neurofibromatosis 2 / diagnosis. Trigeminal Nerve Diseases / diagnosis
  • [MeSH-minor] Child. Codon, Nonsense. Genes, Neurofibromatosis 2. Humans. Male


25. Bouccara D, Kalamarides M, Bozorg Grayeli A, Ambert-Dahan E, Rey A, Sterkers O: [Auditory brainstem implant: indications and results]. Ann Otolaryngol Chir Cervicofac; 2007 Jul;124(3):148-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To summarize the indications and evaluate the Auditory Brainstem Implant (ABI) performances in neurofibromatosis type 2 (NF2) and other otologics indications, as postmeningitis ossified cochlea.
  • MATERIAL AND METHODS: Main and first indication of ABI is NF2.
  • Emergent indications are bilateral total ossified cochlea, vestibular schwannoma with controlateral lesions, cochlear nerve aplasia or inner ear's malformations.
  • RESULTS: In NF2 patients, best results are obtained in cases of smaller vestibular schwannoma and none, or short term, auditory deprivation.
  • CONCLUSION: These results show a clear benefit of ABI in NF2 patients, with or without previous tumor removal, in case of small tumor with a short duration of hearing loss.
  • [MeSH-minor] Brain / pathology. Calcinosis / etiology. Calcinosis / pathology. Cochlear Diseases / etiology. Cochlear Diseases / pathology. Cochlear Nerve / pathology. Cochlear Nerve / surgery. Electrodes, Implanted. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurofibromatosis 2 / complications. Neuroma, Acoustic / complications. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320034.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. McClatchey AI: Neurofibromatosis. Annu Rev Pathol; 2007;2:191-216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis.
  • As familial cancer syndromes, the neurofibromatoses exhibit complex phenotypes, comprising a range of tumor and nontumor manifestations.
  • Although the three recognized forms of neurofibromatosis (NF1, NF2, and schwannomatosis) all feature the development of nervous system tumors, their underlying genetic bases are clearly distinct.
  • Recent progress in delineating the molecular function of the NF1- and NF2-encoded proteins, together with the development and use of manipulable mouse models, has led to important advances in understanding the pathogenesis of many features of neurofibromatosis.
  • An important outcome of the study of neurofibromatosis-associated tumorigenesis has been insight into the more general molecular and cellular bases of nervous system tumors.
  • [MeSH-major] Nervous System Neoplasms / pathology. Neurilemmoma / pathology. Neurofibromatosis 1 / pathology. Neurofibromatosis 2 / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Mice. Neurofibromin 1 / genetics. Neurofibromin 1 / metabolism. Neurofibromin 2 / genetics. Neurofibromin 2 / metabolism. Peripheral Nervous System / metabolism. Peripheral Nervous System / pathology. Schwann Cells / metabolism. Schwann Cells / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039098.001).
  • [ISSN] 1553-4006
  • [Journal-full-title] Annual review of pathology
  • [ISO-abbreviation] Annu Rev Pathol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA113733-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Neurofibromin 2
  • [Number-of-references] 148
  •  go-up   go-down


32. Yang SM, Yu LM, Yu LM, Han DY: [Technique of hearing preservation during acoustic neuroma surgery]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;43(8):564-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Technique of hearing preservation during acoustic neuroma surgery].
  • OBJECTIVE: To explore the possibility of hearing protection in acoustic neurinoma (AN) resection and to evaluate the effect of dynamic auditory monitoring and the effect of oto-endoscope for hearing protection.
  • Fifteen cases were solitary AN, 3 cases were diagnosed as neurofibromatosis II.
  • RESULTS: In all 18 cases, tumors were resected completely in 16 cases, but sub-totally removed in 2 cases which were II neurofibromatosis.
  • According to House-Brackmann grade system, for 18 AN patients 7 days after operation only 50.0% (9/18) were kept at grade I to II , but 88.9% (16/18) were kept at grade I to II 6 months after operation.
  • [MeSH-major] Hearing Loss / prevention & control. Neuroma, Acoustic / surgery. Otologic Surgical Procedures

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959258.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Laskin WB, Fetsch JF, Lasota J, Miettinen M: Benign epithelioid peripheral nerve sheath tumors of the soft tissues: clinicopathologic spectrum of 33 cases. Am J Surg Pathol; 2005 Jan;29(1):39-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign epithelioid peripheral nerve sheath tumors (BEPNSTs) have not been fully characterized, and their relationship to conventional schwannoma and neurofibroma has not been satisfactorily established.
  • Only one patient probably has neurofibromatosis type 1.
  • Immunohistochemical reactivity for Schwann cell-related markers in tumor cells included S-100 protein (20 of 20 cases), collagen type IV (10 of 10), laminin (8 of 8), nerve growth factor receptor, p75(7 of 8), CD57 (6 of 9), and glial fibrillary acidic protein (8 of 15).
  • The remaining 15 cases showed some histologic features suggestive of schwannoma, but their uniform cellularity, absence of nuclear palisading, and presence of a significant CD34-positive spindled cell population in 5 cases led to their classification as "BEPNST of indeterminate histogenesis."
  • Evaluation for loss of heterozygosity in 2 cases demonstrated deletion of genetic material on chromosome 22q and 17q involving NF2 and NF1 loci.
  • However, sequencing of NF2 coding sequences revealed no mutations.
  • Follow-up for 18 patients (median interval, 13.5 years), including 4 patients with tumors exhibiting cytologic atypia, revealed a nondestructive recurrence or persistent disease in 3 patients whose tumors lacked atypia, but no evidence of metastatic spread or tumor-related death.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613855.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neurofibromin 1; 0 / Neurofibromin 2
  •  go-up   go-down


34. Al-Anazi AH, Al-Luwimi IM, Shawarby MA, Mertol T: Mixed vestibular schwannoma and meningioma without neurofibromatosis. Neurosciences (Riyadh); 2009 Oct;14(4):371-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed vestibular schwannoma and meningioma without neurofibromatosis.
  • The co-existence of meningioma and schwannoma as 2 distinct histologic components within the same tumor has been described in neurofibromatosis 2 (NF2), but the co-existence of both tumors without evidence of NF2 is much rarer.
  • Here, we are reporting a case of mixed schwannoma with meningioma without clinical evidence of NF2.
  • In an adult Saudi lady with progressive left-sided hearing loss, left cerebellopontine tumor was diagnosed by MRI, and the histopathological diagnosis revealed that this tumor was composed of vestibular schwannoma and meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048654.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


35. Ng YS, Lyons CJ: Oculomotor nerve palsy in childhood. Can J Ophthalmol; 2005 Oct;40(5):645-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The management of children with oculomotor nerve palsy is complicated by their variable presentation, amblyopia, potential loss of binocularity, and associated neurological disease.
  • Primary aberrant regeneration was the presenting sign in a child with neurofibromatosis type 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391633.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Massager N, Nissim O, Delbrouck C, Devriendt D, David P, Desmedt F, Wikler D, Hassid S, Brotchi J, Levivier M: Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1331-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery.
  • PURPOSE: To analyze the relationship between hearing preservation after gamma knife radiosurgery (GKR) for vestibular schwannoma (VS) and some volumetric and dosimetric parameters of the intracanalicular components of vs. METHODS AND MATERIALS: This study included 82 patients with a VS treated by GKR; all patients had no NF2 disease, a Gardner-Robertson hearing class 1-4 before treatment, a marginal dose of 12 Gy, and a radiologic and audiologic follow-up > or =1 year post-GKR.
  • [MeSH-major] Neuroma, Acoustic / surgery. Radiosurgery

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458446.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Guntinas-Lichius O: Hearing improvement after bevacizumab for neurofibromatosis type 2. N Engl J Med; 2009 Oct 29;361(18):1809-10; author reply 1810-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hearing improvement after bevacizumab for neurofibromatosis type 2.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hearing Loss / drug therapy. Neurofibromatosis 2 / complications. Neuroma, Acoustic / drug therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2009 Jul 23;361(4):358-67 [19587327.001]
  • (PMID = 19864683.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


38. Jaurand MC, Fleury-Feith J: Pathogenesis of malignant pleural mesothelioma. Respirology; 2005 Jan;10(1):2-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations in the tumour suppressor genes, P16/CDKN2A and neurofibromatosis 2 (NF2), are found both in human MPM and in asbestos-exposed Nf2-deficient mice.
  • Despite a ban on asbestos use in Western countries, the incidence of MPM is increasing, due to the long delay between asbestos exposure and diagnosis.
  • [MeSH-minor] Animals. Asbestosis / complications. Cell Transformation, Neoplastic / pathology. Cocarcinogenesis. Genes, Neurofibromatosis 2. Genes, Tumor Suppressor. Humans. Mice. Polyomavirus Infections / complications. Simian virus 40. Tumor Virus Infections / complications


39. Retrosi G, Nanni L, Ricci R, Manzoni C, Pintus C: Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2. J Pediatr Surg; 2009 Jul;44(7):1458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform schwannoma of the esophagus in a child with neurofibromatosis type 2.
  • Schwannoma is a benign neoplasia of the peripheral nerve sheath.
  • According to the existing literature esophageal schwannoma has been reported so far only in adult patients.
  • We report the case of an 11 year old patient with neurofibromatosis, type 2, who underwent surgical excision of a plexiform schwannoma of the esophagus.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Esophagectomy / methods. Neoplasms, Multiple Primary. Neurilemmoma / diagnosis. Neurofibromatosis 2 / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed


40. Soos S, Balasko M, Jech-Mihalffy A, Szekely M, Petervari E: Anorexic vs. metabolic effects of central leptin infusion in rats of various ages and nutritional states. J Mol Neurosci; 2010 May;41(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorexic vs. metabolic effects of central leptin infusion in rats of various ages and nutritional states.
  • In the present experiments, the anorexic (suppressing food intake and body weight) and hypermetabolic (increasing body temperature (Tc), activity, and heart rate (HR), indicating metabolic rate) responses to 7-day-long intracerebroventricular leptin infusion were compared in 2- and 6-month-old normally fed (NF2 and NF6 groups), 6-month-old high-fat-diet-induced obese (HF6), and 6-month-old calorie-restricted (CR6) rats.
  • The anorexic effects were inversely related to fat content: They were most pronounced in NF2, less in NF6, non-significant in HF6 rats, but also absent in CR6 animals of the lowest fat content.
  • In contrast, CR6 rats were hypersensitive to the metabolic effects of leptin infusion (rise in Tc and HR; biotelemetric measurements), NF2 were still sensitive, while NF6 and HF6 rats exhibited moderate or low sensitivity.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1999 May;276(5 Pt 2):R1425-33 [10233036.001]
  • [Cites] Pflugers Arch. 1978 Feb 22;373(2):189-93 [565045.001]
  • [Cites] Endocrinology. 2008 Mar;149(3):1121-8 [18048492.001]
  • [Cites] FASEB J. 2004 Dec;18(15):1949-51 [15388670.001]
  • [Cites] Physiol Behav. 2002 Sep;77(1):65-77 [12213503.001]
  • [Cites] Neuropeptides. 2005 Apr;39(2):103-15 [15752544.001]
  • [Cites] J Neuroendocrinol. 2002 Nov;14(11):887-93 [12421342.001]
  • [Cites] Neuropharmacology. 2000 Jul 24;39(10):1872-9 [10884568.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Oct;56 Spec No 2:81-8 [11730241.001]
  • [Cites] Endocrinology. 1999 Sep;140(9):4015-23 [10465271.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2002 Oct;283(4):R941-8 [12228064.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):4880-9 [15271881.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2613-20 [15044360.001]
  • [Cites] J Pharmacol Toxicol Methods. 2007 Sep-Oct;56(2):218-22 [17596971.001]
  • [Cites] Neuroendocrinology. 2005;82(5-6):256-63 [16721031.001]
  • [Cites] Diabetes. 2000 Mar;49(3):431-5 [10868965.001]
  • [Cites] Dig Dis. 2007;25(2):129-37 [17468548.001]
  • [Cites] J Clin Invest. 2000 Jun;105(12):1827-32 [10862798.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):18933-41 [16687413.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 May;24(5):639-46 [10849588.001]
  • [Cites] Diabetes. 2002 Apr;51(4):1016-21 [11916920.001]
  • (PMID = 19777381.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin
  •  go-up   go-down


41. O'Brien DF, Farrell M, Pidgeon CN: Combined nasal and skull base pathology: adjacent nasal schwannoma and olfactory groove meningioma. Br J Neurosurg; 2005 Oct;19(5):446-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined nasal and skull base pathology: adjacent nasal schwannoma and olfactory groove meningioma.
  • Following surgical removal of the lesion histopathology confirmed the presence of both a nasal schwannoma and an olfactory groove meningioma.
  • This dual pathology may represent a variation of neurofibromatosis type 2 (NF-2).
  • [MeSH-major] Meningioma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neurilemmoma / diagnosis. Nose Neoplasms / diagnosis. Skull Base Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455571.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Kameswaran M, Vasudevan MC, Kumar RS, Nagasundaram J, Natarajan K, Raghunandhan S: Auditory brainstem implantation: The first Indian experience. Indian J Otolaryngol Head Neck Surg; 2005 Jan;57(1):58-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multichannel auditory brainstem implants (ABI) are currently indicated for patients with neurofibromatosis type II (NF2) involving both vestibulocochlear nerves.
  • The implant is usually placed in the lateral recess of the fourth ventricle at the time of tumor resection to stimulate the cochlear nucleus.
  • We report a case of ABI done on a 15-year-old girl with bilateral vestibular schwannomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol Suppl. 2000;(27):11-4 [11211429.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):23-6 [11211432.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):3-7 [11211434.001]
  • [Cites] Otol Neurotol. 2004 Jul;25(4):485-96; discussion 496 [15241227.001]
  • [Cites] Otol Neurotol. 2003 Jan;24(1):79-82 [12544033.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 May;130(5):656-9 [15148193.001]
  • [Cites] Laryngoscope. 2004 Dec;114(12):2135-46 [15564834.001]
  • [Cites] J Laryngol Otol Suppl. 2000;(27):8-10 [11211442.001]
  • (PMID = 23120129.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3451539
  • [Keywords] NOTNLM ; auditory brainsterm unplants / neurofibromatosis
  •  go-up   go-down


43. Chow HY, Stepanova D, Koch J, Chernoff J: p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. PLoS One; 2010 Nov 02;5(11):e13791
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
  • BACKGROUND: NF2 is an autosomal dominant disease characterized by development of bilateral vestibular schwannomas and other benign tumors in central nervous system.
  • Loss of the NF2 gene product, Merlin, leads to aberrant Schwann cell proliferation, motility, and survival, but the mechanisms by which this tumor suppressor functions remain unclear.
  • CONCLUSIONS/SIGNIFICANCE: These results suggest that Pak functions in novel signaling pathways in NF2, and may serve as a useful therapeutic target in this disease.

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):873-91 [10712203.001]
  • [Cites] J Med Genet. 2000 Dec;37(12):897-904 [11106352.001]
  • [Cites] Trends Mol Med. 2001 Apr;7(4):157-62 [11286939.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Circ Res. 2002 Apr 5;90(6):697-702 [11934838.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] J Cell Biol. 2003 Jul 21;162(2):281-91 [12876277.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] J Cell Sci. 2004 Sep 1;117(Pt 19):4343-54 [15331659.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4454-64 [9234703.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5139-44 [9560242.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4328-39 [9687501.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):180-3 [9823899.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):237-49 [16246726.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36609-15 [16129686.001]
  • [Cites] Nat Neurosci. 2006 Feb;9(2):234-42 [16415866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4463-8 [16537381.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Cell Motil Cytoskeleton. 2007 Mar;64(3):143-56 [17183546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3261-6 [17360635.001]
  • [Cites] Biol Cell. 2008 Feb;100(2):97-108 [18199048.001]
  • [Cites] J Cell Sci. 2008 Apr 1;121(Pt 7):933-8 [18319303.001]
  • [Cites] Chem Biol. 2008 Apr;15(4):322-31 [18420139.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5236-45 [18593924.001]
  • [Cites] Oncogene. 2008 Aug 21;27(36):4900-8 [18427546.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7932-7 [18829550.001]
  • [Cites] J Am Chem Soc. 2008 Nov 26;130(47):15764-5 [18973295.001]
  • [Cites] Cancer Metastasis Rev. 2009 Jun;28(1-2):51-63 [19165420.001]
  • [Cites] Exp Neurol. 2009 Jul;218(1):137-44 [19409384.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):579-85 [19350548.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4235-49 [19451229.001]
  • [Cites] Mol Cell. 2010 Apr 23;38(2):236-49 [20417602.001]
  • (PMID = 21072183.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / R01 CA117884; United States / NCI NIH HHS / CA / CA117884
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; EC 2.7.11.1 / p21-Activated Kinases
  • [Other-IDs] NLM/ PMC2970553
  •  go-up   go-down


44. Łaniewski-Wołłk M, Gos M, Koziarski A, Szpecht-Potocka A: Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2. J Appl Genet; 2008;49(3):297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.
  • Point mutation and loss of heterozygosity (LOH) analyses were performed in 12 Polish patients with a classic symptom of NF2 - bilateral vestibular schwannomas (BVS).
  • In 5 patients (41.7%), germline mutations were found in the NF2 gene: 2 previously reported substitutions (c.592C>T and c.52C>T) and 3 novel mutations (c.1001_1002insG, c.1029_1030insCC, c.774_778dupGAATG).
  • In addition, LOH analysis of 30 tumour samples from 10 patients revealed a molecular basis of NF2 in 3 patients (25%) that did not have any germline mutation.
  • The molecular defects in sporadic cases of NF2 are still being discussed.
  • [MeSH-major] Germ-Line Mutation / genetics. Loss of Heterozygosity. Neurofibromatosis 2 / genetics

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 May;38(5):880-5; discussion 885-6 [8727812.001]
  • [Cites] J Med Genet. 2003 Feb;40(2):109-14 [12566519.001]
  • [Cites] Hum Mol Genet. 1994 Mar;3(3):413-9 [8012353.001]
  • [Cites] J Cell Sci. 2001 May;114(Pt 10):1901-12 [11329377.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33093-100 [11432873.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):442-4 [11684412.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):331-42 [8755919.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Apr;42(4):384-91 [15645494.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Pathol. 2006 Mar;208(4):564-73 [16353169.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):534-8 [8882871.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Feb;12(2):117-27 [7535084.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):450-5 [9643284.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • (PMID = 18670066.001).
  • [ISSN] 1234-1983
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Nakamura E, Kaelin WG Jr: Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol; 2006;17(2):97-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors can arise in the context of hereditary cancer syndromes such as von Hippel- Lindau disease, multiple endocrine neoplasia type 2, and neurofibromatosis 1.
  • This review focuses on the genetics of these tumors and suggests a possible link between familial pheochromocytomas/paraganglioma genes and control of neuronal apoptosis during embryological development.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Fetal Development / physiology. Genetic Predisposition to Disease. Paraganglioma / genetics. Pheochromocytoma / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1996 Sep 26;335(13):943-51 [8782503.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Aug;81(8):2881-4 [8768845.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 24;263(2):491-7 [10491320.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):89-95 [14985465.001]
  • [Cites] Genes Dev. 1996 Jun 15;10(12):1455-66 [8666230.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Pathology. 2005 Feb;37(1):10-3 [15875728.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] N Engl J Med. 1993 Nov 18;329(21):1531-8 [8105382.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 1):1717-27 [7798322.001]
  • [Cites] Biochem J. 2004 Aug 1;381(Pt 3):761-7 [15104534.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48690-5 [14506252.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Dec;47(6):707-12 [9497878.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):155-67 [16098468.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] Cell Mol Neurobiol. 1994 Oct;14(5):487-505 [7621509.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26277-80 [9756852.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):247-55 [12086861.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2890-4 [11397905.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12 ):4101-4 [9398721.001]
  • [Cites] J Neurochem. 1999 Jul;73(1):429-32 [10386996.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4568-74 [11134110.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6822-5 [11156372.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5085-92 [11060309.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 9;338(1):627-38 [16153592.001]
  • [Cites] Hum Mol Genet. 2002 Oct 1;11(20):2347-54 [12351569.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5615-21 [14500403.001]
  • [Cites] Am J Pathol. 2006 Feb;168(2):574-84 [16436671.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):237-46 [12086860.001]
  • [Cites] Neuron. 2002 Jan 17;33(2):261-73 [11804573.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] Cell. 1995 Sep 8;82(5):733-42 [7671302.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1181-2 [11323050.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):49-54 [11404820.001]
  • [Cites] Nat Genet. 2000 Nov;26(3):268-70 [11062460.001]
  • [Cites] Neuron. 2002 Jan 17;33(2):156-8 [11804563.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E83 [14691554.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2063-8 [7608256.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):77-85 [15652751.001]
  • [Cites] Hum Mol Genet. 2001 May 1;10 (10 ):1019-27 [11331612.001]
  • [Cites] Neuron. 1995 May;14(5):927-39 [7748560.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 1):659-64 [10458336.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4082-90 [12912907.001]
  • [Cites] J Med Genet. 2002 Sep;39(9):617-22 [12205103.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27509-12 [9346879.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):190-5 [12673678.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] J Cell Biochem. 2004 Jun 1;92 (3):491-501 [15156561.001]
  • [Cites] Medicine (Baltimore). 1991 Jan;70(1):46-66 [1988766.001]
  • [Cites] Hum Mol Genet. 2001 May 1;10 (10 ):1029-38 [11331613.001]
  • [Cites] N Engl J Med. 2002 May 9;346(19):1459-66 [12000816.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):728-33 [14974914.001]
  • [Cites] J Neurochem. 2003 Apr;85(2):318-28 [12675908.001]
  • [Cites] J Med Genet. 1995 Dec;32(12):934-7 [8825918.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4991-5004 [15611513.001]
  • (PMID = 17159241.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9061-61-4 / Nerve Growth Factor; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Number-of-references] 63
  •  go-up   go-down


46. Xiao HJ, Au DK, Yau H, Chow CK, Fan YW, Wei WI: Neurofibromatosis type 2 and auditory brainstem implantation. Chin Med J (Engl); 2007 Aug 20;120(16):1456-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 2 and auditory brainstem implantation.
  • [MeSH-major] Auditory Brain Stem Implantation / methods. Neurofibromatosis 2 / surgery


47. Baser ME, Rai H, Wallace AJ, Evans DG: Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation. Fam Cancer; 2005;4(4):321-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man with a constitutional NF2 missense mutation.
  • Neurofibromatosis 2 (NF2) is caused by inactivating mutations of the NF2 tumor suppressor gene.
  • Somatic NF2 mutations also occur in a high proportion of human primary malignant mesotheliomas.
  • We report an elderly man with NF2, malignant mesothelioma, and a constitutional NF2 missense mutation.
  • The long latent period for mesothelioma in this patient (61 years) raises the possibility that the type of mutant NF2 allele could affect mesothelioma tumorigenesis or progression.
  • [MeSH-major] Genes, Neurofibromatosis 2. Mesothelioma / complications. Mesothelioma / genetics. Neurofibromatosis 2 / genetics. Occupational Exposure / adverse effects. Pleural Neoplasms / genetics
  • [MeSH-minor] Aged. Asbestos / adverse effects. Humans. Male. Mutation, Missense. Neuroma, Acoustic / etiology. Polymerase Chain Reaction


48. Stamenkovic I, Yu Q: Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci; 2010 Sep;11(6):471-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Genetic alterations of neurofibromatosis type 2 (NF2) gene lead to the development of schwannomas, meningiomas, and ependymomas.
  • Mutations of NF2 gene were also found in thyroid cancer, mesothelioma, and melanoma, suggesting that it functions as a tumor suppressor in a wide spectrum of cells.
  • The product of NF2 gene is merlin (moesin-ezrin-radixin-like protein), a member of the Band 4.1 superfamily proteins.
  • Accumulating data also suggested an emerging role of merlin as a negative regulator of growth and progression of several non-NF2 associated cancer types.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:113-43 [11031232.001]
  • [Cites] J Neurosci Res. 2000 Nov 15;62(4):491-502 [11070492.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6778-91 [11118213.001]
  • [Cites] Hum Mol Genet. 1994 Apr;3(4):565-8 [8069299.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23387-90 [8089100.001]
  • [Cites] Hum Mol Genet. 1994 Jul;3(7):1075-9 [7981675.001]
  • [Cites] Gene. 1995 Dec 29;167(1-2):303-6 [8566796.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):354-9 [9537418.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] Nat Med. 1998 Aug;4(8):915-22 [9701243.001]
  • [Cites] Biochim Biophys Acta. 1998 Sep 8;1387(1-2):1-16 [9748471.001]
  • [Cites] Oncogene. 1998 Aug 20;17(7):801-10 [9779996.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] J Neurobiol. 1998 Dec;37(4):487-501 [9858254.001]
  • [Cites] Hum Mol Genet. 1999 Feb;8(2):267-75 [9931334.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):177-81 [9988268.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):182-6 [9988269.001]
  • [Cites] J Cell Sci. 1999 Mar;112 ( Pt 6):895-904 [10036239.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):109-16 [10047517.001]
  • [Cites] Hum Mol Genet. 1999 Aug;8(8):1561-70 [10401006.001]
  • [Cites] Oncogene. 1999 Aug 26;18(34):4788-97 [10490812.001]
  • [Cites] Oncogene. 2004 Nov 18;23(54):8815-25 [15467741.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1380-5 [15746036.001]
  • [Cites] Cell. 2005 Mar 11;120(5):675-85 [15766530.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2076-86 [15688006.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12517-22 [15699051.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Exp Cell Res. 2005 Aug 1;308(1):177-87 [15913605.001]
  • [Cites] Cell. 2005 Aug 12;122(3):421-34 [16096061.001]
  • [Cites] Oncogene. 2005 Aug 11;24(34):5355-64 [16007223.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Sep 23;335(2):385-92 [16083858.001]
  • [Cites] Science. 2005 Aug 12;309(5737):1074-8 [16099986.001]
  • [Cites] Dev Cell. 2005 Sep;9(3):377-88 [16139226.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] J Cell Biol. 2005 Oct 24;171(2):361-71 [16247032.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 24;340(4):1151-7 [16405865.001]
  • [Cites] Cell. 2006 Jan 27;124(2):267-73 [16439203.001]
  • [Cites] Annu Rev Physiol. 2006;68:491-505 [16460281.001]
  • [Cites] Hum Mol Genet. 2006 Apr 1;15(7):1059-70 [16497727.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Apr;7(4):253-64 [16607288.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Semin Pediatr Neurol. 2006 Mar;13(1):21-6 [16818172.001]
  • [Cites] Eur J Cell Biol. 2006 Aug;85(8):769-83 [16762451.001]
  • [Cites] Nature. 2006 Aug 3;442(7102):576-9 [16885985.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10 [16894141.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5960-8 [16652148.001]
  • [Cites] Genes Dev. 2006 Oct 1;20(19):2687-700 [17015431.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1175-80 [16998483.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1167-74 [16998484.001]
  • [Cites] Curr Biol. 2006 Nov 7;16(21):2090-100 [16996265.001]
  • [Cites] Curr Biol. 2006 Nov 7;16(21):2081-9 [16996266.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):450-8 [17049657.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7757-64 [9516485.001]
  • [Cites] J Biol Chem. 1999 Dec 3;274(49):34507-10 [10574907.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1699-712 [10669747.001]
  • [Cites] Development. 2000 Mar;127(6):1315-24 [10683183.001]
  • [Cites] Cell. 2000 Apr 28;101(3):259-70 [10847681.001]
  • [Cites] Nat Cell Biol. 2000 Jul;2(7):407-14 [10878805.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:106-18; discussion 118-20 [10911909.001]
  • [Cites] Hum Pathol. 2008 Nov;39(11):1582-9 [18703216.001]
  • [Cites] Biofactors. 2009 Jul-Aug;35(4):338-45 [19484742.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5032-9 [19671848.001]
  • [Cites] Genet Med. 2009 Sep;11(9):599-610 [19652604.001]
  • [Cites] Am J Pathol. 2001 Jan;158(1):57-62 [11141479.001]
  • [Cites] Neuropathology. 2000 Sep;20(3):153-60 [11132929.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):747-55 [11257108.001]
  • [Cites] Trends Mol Med. 2001 Apr;7(4):157-62 [11286939.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Biochem J. 2001 Jun 1;356(Pt 2):377-86 [11368764.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7621-9 [11106646.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):33093-100 [11432873.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34728-37 [11457831.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6309-14 [11607833.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):442-4 [11684412.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Curr Opin Cell Biol. 2002 Feb;14(1):104-9 [11792551.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] Genomics. 2002 Jan;79(1):63-76 [11827459.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1233-41 [11850843.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10332-6 [11756419.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):354-62 [12118253.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Cell. 2002 Aug 23;110(4):467-78 [12202036.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):5990-7 [12203111.001]
  • [Cites] Hum Mol Genet. 2002 Sep 15;11(19):2269-78 [12217955.001]
  • [Cites] Mol Cells. 2002 Aug 31;14(1):108-14 [12243339.001]
  • [Cites] Science. 2002 Oct 18;298(5593):597-600 [12228720.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3167-78 [12444101.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3179-89 [12444102.001]
  • [Cites] Genes Dev. 2002 Dec 1;16(23):3074-86 [12464636.001]
  • [Cites] Curr Opin Neurol. 2003 Feb;16(1):27-33 [12544854.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):209-21 [12558984.001]
  • [Cites] Nat Cell Biol. 2003 May;5(5):410-21 [12717440.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4398-405 [12853976.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33334-41 [12807903.001]
  • [Cites] Cell. 2003 Aug 22;114(4):445-56 [12941273.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):41167-72 [12896975.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):389-99 [14566860.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Int J Oncol. 2003 Dec;23(6):1493-500 [14612918.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2717-24 [15087385.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):528-39 [15229478.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30265-73 [15123692.001]
  • [Cites] EMBO J. 2004 Sep 15;23(18):3677-88 [15343267.001]
  • [Cites] EMBO J. 1989 Dec 20;8(13):4133-42 [2591371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8297-301 [1924289.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1039-48 [1955455.001]
  • [Cites] J Cell Biol. 1993 Jan;120(1):129-39 [8416983.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Cancer Res. 1994 Jan 15;54(2):330-5 [7506121.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):185-92 [8162073.001]
  • [Cites] Curr Opin Cell Biol. 1994 Feb;6(1):136-41 [8167019.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] Hum Mol Genet. 1994 Apr;3(4):559-64 [8069298.001]
  • [Cites] Curr Biol. 2009 Nov 3;19(20):1692-702 [19836237.001]
  • [Cites] J Cell Sci. 2009 Nov 15;122(Pt 22):4141-9 [19910496.001]
  • [Cites] Cancer Res. 2010 Mar 15;70(6):2455-64 [20197461.001]
  • [Cites] J Neurosurg. 2011 Feb;114(2):359-66 [19943731.001]
  • [Cites] J Cell Biol. 1996 May;133(4):843-52 [8666669.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21049-53 [8702870.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1239-47 [8808698.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):534-8 [8882871.001]
  • [Cites] Curr Opin Cell Biol. 1997 Feb;9(1):70-5 [9013673.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1253-65 [9171370.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27913-8 [9346940.001]
  • [Cites] J Cell Sci. 1997 Sep;110 ( Pt 18):2249-60 [9378774.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] J Cell Biol. 1998 Feb 23;140(4):885-95 [9472040.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):520-7 [17234759.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):836-50 [16953231.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2103-19 [17210637.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):331-8 [17277767.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Dev Biol. 2007 Apr 1;304(1):102-15 [17258190.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):222-9 [17442573.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Hum Mol Genet. 2007 Jul 15;16(14):1742-51 [17566081.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):341-6 [17823551.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1120-33 [17889654.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] Mol Carcinog. 2007 Oct;46(10):865-71 [17538946.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2747-61 [17974916.001]
  • [Cites] Curr Biol. 2007 Nov 6;17(21):1864-70 [17964162.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):32-54 [17980164.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):3-15 [17881309.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):256-62 [17971776.001]
  • [Cites] Mol Cell Biol. 2008 Feb;28(4):1274-84 [18086884.001]
  • [Cites] Brain. 2008 Mar;131(Pt 3):606-15 [17940085.001]
  • [Cites] J Biol Chem. 2008 Feb 29;283(9):5496-509 [18158288.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2426-36 [18227151.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2592-8 [18413727.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2789-94 [18413746.001]
  • [Cites] J Cell Mol Med. 2008 Apr;12(2):374-90 [18182063.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1231-42 [18369314.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2705-15 [17998937.001]
  • [Cites] Mol Cell. 2008 Apr 25;30(2):123-35 [18439892.001]
  • [Cites] Cell Signal. 2008 Jul;20(7):1237-47 [18255267.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3233-43 [18071304.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2806-12 [18539958.001]
  • [Cites] Exp Cell Res. 2008 Jul 1;314(11-12):2279-88 [18486129.001]
  • [Cites] Nat Cell Biol. 2008 Jul;10(7):837-48 [18568018.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5733-42 [18632626.001]
  • [Cites] Cell Stem Cell. 2008 Aug 7;3(2):221-7 [18682243.001]
  • [Cites] Dev Cell. 2008 Aug;15(2):209-19 [18694561.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27534-46 [18640976.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1204-12 [18953429.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6751-60 [18980968.001]
  • [Cites] Mol Cell Biol. 2009 Mar;29(6):1472-86 [19103750.001]
  • [Cites] Dev Cell. 2009 Mar;16(3):433-44 [19289088.001]
  • [Cites] J Invest Dermatol. 2009 Jun;129(6):1321-4 [19434087.001]
  • [Cites] Trends Cell Biol. 2009 May;19(5):198-206 [19345106.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4235-49 [19451229.001]
  • (PMID = 20491622.001).
  • [ISSN] 1875-5550
  • [Journal-full-title] Current protein & peptide science
  • [ISO-abbreviation] Curr. Protein Pept. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA135158-02; United States / NCI NIH HHS / CA / R01 CA135158-02; United States / NCI NIH HHS / CA / CA150355-01A1; United States / NCI NIH HHS / CA / R01 CA150355-01A1; United States / NCI NIH HHS / CA / 1R01CA150355-01A1; United States / NCI NIH HHS / CA / R01 CA135158; United States / NCI NIH HHS / CA / R01 CA150355; United States / NCI NIH HHS / CA / 1R01CA135158-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 2
  • [Other-IDs] NLM/ NIHMS236013; NLM/ PMC2946555
  •  go-up   go-down


49. Galcheva-Gargova Z, Zhidkova N, Geisler S, Ozug J, Wudyka S, Gunay NS, Qi YW, Shriver Z, Venkataraman G: Overexpression of Merlin in B16F10 mouse melanoma cells reduces their metastatic activity: role of the cell surface heparan sulfate glycosaminoglycans. Int J Oncol; 2008 Jun;32(6):1237-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Merlin, the protein product of the neurofibromatosis type 2 gene (NF2) acts as a tumor suppressor in mice and humans.
  • In this study, melanoma B16F10 cells were engineered to overexpress the NF2 gene by establishing stable transductants.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497985.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Neurofibromin 2; 9050-30-0 / Heparitin Sulfate
  •  go-up   go-down


50. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO: Reduced apoptosis rates in human schwannomas. Brain Pathol; 2005 Jan;15(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas, tumors originating from Schwann cells, represent a frequent neurological tumor and can occur both in a genetic disorder called neurofibromatosis type 2 (NF2) and sporadically.
  • In both cases the genetic background is identical as all schwannomas are caused by biallelic mutations in the tumor suppressor gene NF2 coding for merlin.
  • Mutations in this gene have also been found to be responsible for 50% to 60% of spontaneous and 100% of the NF2 associated meningiomas.
  • The NF2 gene product, merlin, links transmembrane proteins to the cytoskeleton and is involved in intracellular signaling processes.
  • It has previously been shown that reexpression of wild-type merlin in primary human schwannoma cells leads to an increase in the number of apoptotic cells.
  • Here, we report in vivo and in vitro evidence that the basal apoptosis rate of primary human schwannoma cells is reduced in comparison to that of normal Schwann cells, supporting the idea that in this benign tumor type, apoptosis has a role in tumorigenesis.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779232.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


51. Bhatoe HS, Singh P, Dutta V: Intraventricular meningiomas: a clinicopathological study and review. Neurosurg Focus; 2006;20(3):E9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this retrospective analysis, the authors describe the cases of 12 patients who had received a diagnosis of intraventricular meningioma and underwent surgery for the tumors.
  • Features of neurofibromatosis Type 2 were present in two of the women.
  • Nine of the tumors were located in the lateral ventricles, one was in the third ventricle, and two were in the fourth ventricle.
  • Excision was performed using the parietooccipital (trigonal) approach for lateral ventricle tumors, the transcortical-transventricular route for the third ventricle tumor, and suboccipital craniectomy for fourth ventricle tumors.
  • Although they are commonly seen in the lateral ventricles, they occur in the third and fourth ventricles as well.
  • Presentation is in the form of raised ICP with no localizing features; therefore the diagnosis is based on imaging studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599425.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


52. Akinci A, Acaroglu G, Guven A, Degerliyurt A: Refractive errors in neurofibromatosis type 1 and type 2. Br J Ophthalmol; 2007 Jun;91(6):746-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refractive errors in neurofibromatosis type 1 and type 2.
  • OBJECTIVE: To document the prevalence of refractive errors in patients with neurofibromatosis type 1 (NF1) and type 2 (NF2) and to compare it with that of age- and sex-matched controls.
  • METHODS: 82 patients with NF1, 21 patients with NF2 and 103 age- and sex-matched controls were evaluated in this prospective observational case-control study.
  • RESULTS: The prevalence of myopia was 23.1% in patients with NF1, 23.8% in patients with NF2 and 16.5% in age- and sex-matched controls.
  • These differences were significant (p<0.03, p<0.03), and adjusting for intelligence, education, height, weight and BMI increased the significance of this finding (p<0.001, p<0.001).
  • CONCLUSION: A high prevalence of myopia seems to be an additional feature of NF1 and NF2.
  • [MeSH-major] Neurofibromatosis 1 / complications. Neurofibromatosis 2 / complications. Refractive Errors / etiology


53. Zuccala' A, Di Nicolo' P, Fiorenza S, Lifrieri F, Rapana' R: [The sympathetic system and neuroendocrine hypertension]. G Ital Nefrol; 2008 Mar-Apr;25(2):203-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sporadic pheochromocytoma is a rare tumor that should be taken into account in patients with hypertensive crisis, arrhythmias, and panic disorder.
  • Familial pheochromocytoma is frequently found in subjects with von Hippel-Lindau disease, multiple endocrine neoplasia type II, neurofibromatosis, and SDHD gene mutations.
  • Plasma free metanephrines have been shown to have high sensitivity and specificity in the biochemical diagnosis of sporadic and familial pheochromocytoma.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18350500.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 49
  •  go-up   go-down


54. Evans DG, Maher ER, Baser ME: Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms. J Med Genet; 2005 Aug;42(8):630-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms.
  • We compared the ratio of frameshift to nonsense mutations in three diseases that are related to the NF2 tumour suppressor gene: classic neurofibromatosis 2 (NF2), caused by germline NF2 mutations; mosaic NF2; and unilateral sporadic vestibular schwannoma (USVS), caused by somatic NF2 inactivation.
  • Nonsense mutations predominated in both classic and mosaic NF2, but the ratio of nonsense to frameshift mutations was reversed in USvs. Moreover, in USVS patients, the ratio of somatic frameshift to nonsense mutations increased significantly with increasing age at diagnosis.
  • Similar studies for other familial cancer genes may provide further evidence for this hypothesis.
  • [MeSH-major] Codon, Nonsense. DNA Repair / physiology. Frameshift Mutation. Genes, Neurofibromatosis 2. Germ-Line Mutation
  • [MeSH-minor] Age Factors. Genetic Predisposition to Disease. Humans. Mosaicism. Neuroma, Acoustic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2000 Jan;66(1):84-91 [10631138.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] Genetics. 2000 Jul;155(3):1359-67 [10880494.001]
  • [Cites] Am J Otol. 2000 Sep;21(5):690-4 [10993460.001]
  • [Cites] Environ Mol Mutagen. 2000;36(4):301-11 [11152563.001]
  • [Cites] Genes Cells. 2001 May;6(5):441-54 [11380622.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7587-600 [11604495.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2920-6 [11753967.001]
  • [Cites] Ann N Y Acad Sci. 2001 Apr;928:113-20 [11795502.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2410-8 [11884623.001]
  • [Cites] Mutat Res. 2002 Mar 20;500(1-2):135-45 [11890943.001]
  • [Cites] Gene. 2002 May 1;289(1-2):41-8 [12036582.001]
  • [Cites] Mech Ageing Dev. 2002 Apr 30;123(8):907-15 [12044939.001]
  • [Cites] Nucleic Acids Res. 2002 Aug 15;30(16):3566-73 [12177298.001]
  • [Cites] Hum Mutat. 2003 Jan;21(1):12-27 [12497628.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4257-65 [12833148.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):168-70 [14755273.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):29-39 [15000147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7624-9 [15123826.001]
  • [Cites] Biochim Biophys Acta. 2004 Aug 12;1679(2):95-106 [15297143.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):231-9 [15190457.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Aug 20;321(2):455-61 [15358197.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Arch Toxicol. 1997;71(5):332-5 [9137812.001]
  • [Cites] Hum Mutat. 1999;13(6):464-75 [10408776.001]
  • [Cites] Mutat Res. 2000 Apr 28;459(3):195-202 [10812331.001]
  • (PMID = 16061561.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon, Nonsense
  • [Other-IDs] NLM/ PMC1736122
  •  go-up   go-down


55. Franzin A, Spatola G, Serra C, Picozzi P, Medone M, Milani D, Castellazzi P, Mortini P: Evaluation of hearing function after Gamma Knife surgery of vestibular schwannomas. Neurosurg Focus; 2009 Dec;27(6):E3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of hearing function after Gamma Knife surgery of vestibular schwannomas.
  • OBJECT: Due to technological advances in neuroradiology in recent years, incidental diagnoses of vestibular schwannomas (VSs) have increased.
  • METHODS: Of all patients treated in the authors' hospital between 2001 and 2007, they retrospectively studied 50 patients with a unilateral VS in whom there was serviceable hearing (Gardner-Robertson [GR] Class I or II).
  • Additional inclusion criteria were: no Type 2 neurofibromatosis, no previous treatment, and at least 6 months' follow-up of neuroradiological and audiological data.
  • Serviceable hearing was preserved in 34 patients (68%): 21 (62%) with GR Class I hearing and 13 (38%) with GR Class II hearing.
  • In 19 (58%) of 33 patients with GR Class I function before GKS the same class was maintained posttreatment; 29 (88%) maintained functional hearing (GR Class I or II).
  • Significant prognostic factors for maintaining serviceable hearing were GR Class I function before treatment, symptoms at presentation, patient age younger than 54 years, and Koos Stage T1 disease.
  • The prescribed dose of 13 Gy appears to represent an excellent compromise between controlling the disease and preserving auditory function.
  • [MeSH-major] Hearing Loss / prevention & control. Neuroma, Acoustic / surgery. Postoperative Complications / prevention & control. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951056.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Yu H, Ye L, Mansel RE, Zhang Y, Jiang WG: Clinical implications of the influence of Ehm2 on the aggressiveness of breast cancer cells through regulation of matrix metalloproteinase-9 expression. Mol Cancer Res; 2010 Nov;8(11):1501-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ehm2, a member of NF2/ERM/4.1 superfamily, has been indicated in disease progression and metastasis of prostate cancer.
  • Higher levels of Ehm2 transcripts were correlated with disease progression, metastasis, and poor prognosis.
  • Disease-free survival of the patients with lower levels of Ehm2 was 135.8 (95% confidence interval, 125.1-146.5) months, significantly longer compared with 102.5 (95% confidence interval, 78.7-126.4) months of patients with higher levels of Ehm2 expression (P = 0.039).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 21047774.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / EPB41L4B protein, human; 0 / RNA, Catalytic; 0 / hammerhead ribozyme; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


57. Mazzoni A, Dubey SP, Poletti AM, Colombo G: Sporadic acoustic neuroma in pediatric patients. Int J Pediatr Otorhinolaryngol; 2007 Oct;71(10):1569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic acoustic neuroma in pediatric patients.
  • OBJECTIVE: Sporadic acoustic neuroma, usually occur between the ages of 40 and 70 years, are very rare in children.
  • We review the experiences of 10 cases of sporadic (non-NF2) acoustic neuromas in pediatric patients.
  • Among these almost 900 cases were acoustic neuromas.
  • Postoperatively seven cases the facial nerve recovered to grade I, and one each to grade II and grade VI of House-Brackmann classification.
  • [MeSH-major] Neuroma, Acoustic / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Hearing Loss, Sensorineural / diagnosis. Hearing Loss, Sensorineural / epidemiology. Humans. Incidence. Male. Paresis / diagnosis. Paresis / epidemiology. Paresis / etiology. Postoperative Complications. Prevalence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643497.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


58. Martinez-Glez V, Bello MJ, Franco-Hernandez C, De Campos JM, Isla A, Vaquero J, Rey JA: Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas. Int J Mol Med; 2005 Oct;16(4):771-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DAL-1/41B gene (differentially expressed in adenocarcinoma of the lung), located in the chromosome 18p11.3 region, belongs to the protein family 4.1 (membrane-associated proteins), which includes the product of the NF2 gene (merlin), and the proteins, ezrin, radixin, and moesin.
  • We found the following sequence variations; Ala555Thr (G1663A in exon 13) and Thr950Lys (C2849A in exon 19) in two cases each, and one case with a 5pb deletion (del taaaa) in intron 18.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142420.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


59. Bosch MM, Wichmann WW, Boltshauser E, Landau K: Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch Ophthalmol; 2006 Mar;124(3):379-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic nerve sheath meningiomas in patients with neurofibromatosis type 2.
  • OBJECTIVE: To determine the prevalence of optic nerve sheath meningiomas (ONSMs) in patients with neurofibromatosis type 2 (NF2).
  • METHODS: An observational retrospective case series of 30 consecutive patients with NF2 referred to an academic ophthalmology unit from November 1, 1991, through August 31, 2003.
  • Diagnosis of ONSM was made based on typical neuroradiologic and clinical features in 7 patients and on histologic criteria in 1.
  • RESULTS: Eight of 30 patients harbored unilateral (n = 6) or bilateral (n = 2) ONSMs.
  • CONCLUSIONS: There is a strong association between ONSMs and NF2 that parallels the well-known association of optic nerve gliomas with NF1.
  • Physicians should be aware of the possibility that patients with ONSMs may also have NF2.
  • [MeSH-major] Meningioma / diagnosis. Neurofibromatosis 2 / diagnosis. Optic Nerve Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16534058.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L: Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics; 2005 Feb;36(1):21-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
  • BACKGROUND: Neurofibromatosis type 2 (NF2) is an autosomal dominant disease characterised by the development of multiple nervous system tumours, ocular abnormalities, and skin tumours.
  • Although classically considered a disease of adults, initial signs and/or symptoms may be evident in childhood and are often unrecognised.
  • OBJECTIVES: The aim of this study was to identify the earliest clinical presentations of NF2 and to characterise the clinical course and outcome in children with NF2.
  • METHODS: We have performed a retrospective (years 1990-1998) and prospective (years 1998-2004) study of 24 patients (10 males, 14 females; currently aged 4 to 22 years) fulfilling the revised (Manchester) NF2 criteria seen at the Universities of Catania and Rome, Italy.
  • RESULTS: Causes of referral prior to a definitive diagnosis of NF2 were:.
  • 3) Neurological dysfunction: seizures secondary to intracranial meningioma (n = 1) or vestibular schwannomas (VS) (n = 1), neurological dysfunction related to brainstem and/or spinal cord tumours (n = 7), isolated and multiple cranial nerve deficits (n = 10), and peripheral neuropathy secondary to schwannomas (n = 4);.
  • Molecular genetic analysis of the NF2 gene revealed typical truncating mutations in all the 5 familial cases and in 2/10 sporadic cases analysed.
  • CONCLUSIONS: Children with NF2 often first come to medical attention because of ocular, subtle skin, or neurological problems the significance of which is realised when they later present with more classical symptoms due to bilateral VS or other intracranial tumours.
  • [MeSH-major] Neurofibromatosis 2 / physiopathology. Otorhinolaryngologic Diseases / etiology


61. Patil S, Perry A, Maccollin M, Dong S, Betensky RA, Yeh TH, Gutmann DH, Stemmer-Rachamimov AO: Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol; 2008 Oct;18(4):517-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The INI1/SMARCB1 protein product (INI1), a component of a transcription complex, was recently implicated in the pathogenesis of schwannomas in two members of a single family with familial schwannomatosis.
  • To determine if this finding could be extended to all tumors arising in familial schwannomatosis, and how it compares with other multiple schwannoma syndromes [sporadic schwannomatosis and neurofibromatosis 2 (NF2)] as well as to sporadic, solitary schwannomas, we performed an immunohistochemistry analysis on 45 schwannomas from patients with multiple schwannoma syndromes and on 38 solitary, sporadic schwannomas from non-syndromic patients.
  • A mosaic pattern of INI1 expression was seen in 93% of tumors from familial schwannomatosis patients, 55% of tumors from sporadic schwannomatosis, 83% of NF2-associated tumors and only 5% of solitary, sporadic schwannomas.
  • These results confirm a role for INI1/SMARCB1 in multiple schwannoma syndromes and suggest that a different pathway of tumorigenesis occurs in solitary, sporadic tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2001 May 28;20(24):3067-75 [11420722.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):1968-74 [12821741.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Sep;17(1):45-55 [8889506.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):951-8 [15761491.001]
  • [Cites] Mod Pathol. 2006 May;19(5):717-25 [16528370.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):279-84 [16261613.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1293-302 [9399891.001]
  • (PMID = 18422762.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS024279-20A29010; United States / NINDS NIH HHS / NS / P01 NS024279-20A29010
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / Neurofibromin 2; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS114873; NLM/ PMC2743242
  •  go-up   go-down


62. Zhao ZS, Manser E: Do PAKs make good drug targets? F1000 Biol Rep; 2010;2:70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The genetic loss of NF2 (neurofibromatosis type 2) leading to increased cell proliferation through a Ras-Rac-PAK pathway may represent a good test system to analyze this new PAK inhibitor.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21173843.001).
  • [ISSN] 1757-594X
  • [Journal-full-title] F1000 biology reports
  • [ISO-abbreviation] F1000 Biol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2989626
  •  go-up   go-down


63. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, Favrot MC, Plantaz D: Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet; 2006 Apr 1;166(1):74-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ependymomas (EP) represent the third most frequent type of central nervous system (CNS) tumor of childhood, after astrocytomas and medulloblastomas.
  • The present objective was, for a sample of 27 children with intracranial EP and 7 with CPP, to describe and compare the methylation status of 19 genes (with current HUGO symbol, if any): p15INK4a (CDKN2B), p16INK4a and p14ARF (both CDKN2A), APC, RB1, RASSF1A (RASSF1), BLU (ZMYND10) FHIT, RARB, MGMT, DAPK (DAPK1), ECAD (CDH1), CASP8, TNFRSF10C, TNFRSF10D, FLIP (CFLAR), INI1 (SMARCB1), TIMP3, and NF2.


64. Holland K, Kaye AH: Spinal tumors in neurofibromatosis-2: management considerations - a review. J Clin Neurosci; 2009 Feb;16(2):169-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal tumors in neurofibromatosis-2: management considerations - a review.
  • Neurofibromatosis Type 2 (NF-2) is a distinct clinical entity, characterized by multiple intracranial and spinal tumors.
  • While bilateral vestibular schwannomas are the pathological hallmark of the disease, significant morbidity in NF-2 is attributable to the presence of both intramedullary and extramedullary spinal tumors.
  • With the advent of MRI as a screening modality, multiple, extensive spinal tumors in the NF-2 population are often seen, which may be clinically quiescent at the time of initial diagnosis.
  • All NF-2 patients should have routine screening with full spinal MRI at the time of diagnosis, regardless of symptoms.
  • [MeSH-major] Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / therapy. Spinal Neoplasms / diagnosis. Spinal Neoplasms / therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101145.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 44
  •  go-up   go-down


65. Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet; 2008 Jun;45(6):332-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.
  • BACKGROUND: Schwannomatosis is a rare condition characterised by multiple schwannomas and lack of involvement of the vestibular nerve.
  • A recent report identified bi-allelic mutations in the SMARCB1/INI1 gene in a single family with schwannomatosis.
  • We aimed to establish the contribution of the SMARCB1 and the NF2 genes to sporadic and familial schwannomatosis in our cohort.
  • METHODS: We performed DNA sequence and dosage analysis of SMARCB1 and NF2 in 28 sporadic cases and 15 families with schwannomatosis.
  • In addition, in all affected individuals with SMARCB1 mutations and available tumour tissue, we detected bi-allelic somatic inactivation of the NF2 gene.
  • CONCLUSION: In contrast to the recent report where no NF2 mutations were identified in a schwannomatosis family with SMARCB1 mutations, in our cohort, a four hit model with mutations in both SMARCB1 and NF2 define a subset of patients with schwannomatosis.


66. Roser F, Ebner FH, Ritz R, Samii M, Tatagiba MS, Nakamura M: Management of skull based meningiomas in the elderly patient. J Clin Neurosci; 2007 Mar;14(3):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The demographic evolution of Western society together with availability of modern imaging techniques leads to an increasing diagnosis of meningioma patients over 70 years of age.
  • DESIGN: Forty-three patients aged over 70 years were analyzed and matched in a retrospective study with a younger group of 89 patients according to tumour size, histology, symptoms, recurrence and presence of neurofibromatosis II.
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Humans. Middle Aged. Morbidity. Neoplasm Recurrence, Local / mortality. Neurofibromatosis 2 / mortality. Neurofibromatosis 2 / surgery. Patient Selection. Postoperative Complications / mortality. Quality of Life. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258130.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


67. Kobayashi H, Ishii N, Murata J, Saito H, Kubota KC, Nagashima K, Iwasaki Y: Cystic meningioangiomatosis. Pediatr Neurosurg; 2006;42(5):320-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 14-year-old boy without any stigmata of neurofibromatosis type 2 presented intractable complex partial and generalized seizures since the age of 12 years.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16902347.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Rice JM: Inducible and transmissible genetic events and pediatric tumors of the nervous system. J Radiat Res; 2006;47 Suppl B:B1-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the nervous system most often occur in both children and adults as sporadic events with no family history of the disease, but they are also among the clinical manifestations of a significant number of familial cancer syndromes, including familial retinoblastoma, neurofibromatosis 1 and 2, tuberous sclerosis, and Cowden, Turcot, Li-Fraumeni and nevoid basal cell carcinoma (Gorlin) syndromes.
  • These genes include RB1, NF1, NF2, TSC1, TSC2, TP53, PTEN, APC, hMLH1, hPSM2, and PTCH, most of which function as tumor suppressor genes.


69. Feucht M, Kluwe L, Mautner VF, Richard G: Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2. Arch Ophthalmol; 2008 Oct;126(10):1376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2.
  • BACKGROUND: Neurofibromatosis 2 (NF2) is an autosomal dominant disease that is characterized by nervous system tumors and ocular abnormalities.
  • OBJECTIVE: To investigate genotype-phenotype correlations demonstrated for NF2-associated nervous system tumors, cataracts, and retinal lesions.
  • METHODS: Forty-eight patients with NF2 from a tertiary neurological referral center underwent screening for constitutional NF2 mutations with multiple screening methods.
  • CONCLUSIONS: To our knowledge, this is the first genetic, clinical, and angiographic characterization of retinal abnormalities in NF2.
  • Clinical Relevance Retinal abnormalities, which can be revealed by means of fluorescein angiography, are more common in patients with NF2 who have nonsense or frameshift mutations.
  • [MeSH-major] Fluorescein Angiography. Frameshift Mutation. Genes, Neurofibromatosis 2. Neurofibromatosis 2 / epidemiology. Neurofibromatosis 2 / genetics. Retinal Diseases / epidemiology. Retinal Diseases / genetics
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Analysis of Variance. Cataract / diagnosis. Cataract / genetics. Causality. Child. Codon, Nonsense. Cohort Studies. Comorbidity. Confidence Intervals. Female. Genetic Predisposition to Disease. Genetic Testing. Genotype. Humans. Logistic Models. Male. Middle Aged. Odds Ratio. Phenotype. Severity of Illness Index

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Retinal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852415.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense
  •  go-up   go-down


70. McLaughlin ME, Pepin SM, Maccollin M, Choopong P, Lessell S: Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol; 2007 Mar;125(3):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular pathologic findings of neurofibromatosis type 2.
  • OBJECTIVE: To gain insight into the pathogenesis of neurofibromatosis type 2 (NF2) by investigating the ocular manifestations of this disease.
  • METHODS: Using standard histologic techniques, immunohistochemistry, and electron microscopy, we described the ocular pathologic findings of a 34-year-old woman who died from complications of NF2.
  • RESULTS: We identified 3 types of NF2-associated lesions: juvenile posterior subcapsular cataracts, epiretinal membranes, and an intrascleral schwannoma.
  • CONCLUSIONS: Our analysis indicated that dysplastic lens cells accumulate just anterior to the posterior lens capsule in juvenile posterior subcapsular cataracts and that dysplastic Müller cells may be a major component of NF2-associated epiretinal membranes.
  • Clinical Relevance Our findings suggest that a subset of glial cells with epithelial features (Schwann cells, ependymal cells, and Müller cells) may be particularly sensitive to loss of the NF2 gene.
  • Understanding the molecular basis for this sensitivity may lead to novel strategies for treating NF2.
  • [MeSH-major] Cataract / pathology. Epiretinal Membrane / pathology. Eye Neoplasms / pathology. Neurilemmoma / pathology. Neurofibromatosis 2 / pathology. Scleral Diseases / pathology


71. Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP: Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum Mutat; 2007 Jan;28(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings.
  • The NF2 tumor suppressor gene on chromosome 22 is a member of the protein 4.1 family of cytoskeletal elements.
  • A number of single- and multiple-tumor phenotypes have been linked to alterations of NF2 since its characterization in 1993.
  • We present a meta-analysis of 967 constitutional and somatic NF2 alterations from 93 published reports, along with 59 additional unpublished events identified in our laboratory and 115 alterations identified in clinical samples submitted to the Massachusetts General Hospital (MGH) Neurogenetics DNA Diagnostic Laboratory.
  • There was no statistically significant difference in mutation type or exon distribution between published constitutional events and those found by the clinical laboratory.
  • [MeSH-major] Genes, Neurofibromatosis 2. Molecular Diagnostic Techniques / methods. Mutation

  • Genetics Home Reference. consumer health - NF2 gene.
  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2006 Wiley-Liss, Inc.
  • (PMID = 16983642.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1 R01 NS40527
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


72. Denayer E, Brems H, de Cock P, Evans GD, Van Calenbergh F, Bowers N, Sciot R, Debiec-Rychter M, Vermeesch JV, Fryns JP, Legius E: Pathogenesis of vestibular schwannoma in ring chromosome 22. BMC Med Genet; 2009;10:97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of vestibular schwannoma in ring chromosome 22.
  • Clinical features of neurofibromatosis type 1 and 2 as well as different tumour types have been reported in patients with ring chromosome 22.
  • At the age of 20 years she was diagnosed with a unilateral vestibular schwannoma.
  • Tumour cells were analyzed by karyotyping, array CGH and NF2 mutation analysis.
  • Genetic analysis of vestibular schwannoma tissue revealed loss of the ring chromosome 22 and a somatic second hit in the NF2 gene on the remaining chromosome 22.
  • CONCLUSION: We conclude that tumours can arise by the combination of loss of the ring chromosome and a pathogenic NF2 mutation on the remaining chromosome 22 in patients with ring chromosome 22.
  • Our findings indicate that patients with a ring 22 should be monitored for NF2-related tumours starting in adolescence.
  • [MeSH-major] Chromosomes, Human, Pair 22. Neuroma, Acoustic / genetics. Ring Chromosomes
  • [MeSH-minor] Adult. Female. Genes, Neurofibromatosis 1. Genes, Neurofibromatosis 2. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Magnetic Resonance Imaging. Mutation. Oligonucleotide Array Sequence Analysis. Phenotype. Sequence Analysis, DNA


73. Ye K: Phosphorylation of merlin regulates its stability and tumor suppressive activity. Cell Adh Migr; 2007 Oct-Dec;1(4):196-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis-2 (NF2) tumor suppressor protein, merlin or schwannomin, inhibits cell proliferation by modulating the growth activities of its binding partners, including the cell surface glycoprotein CD44, membrane-cytoskeleton linker protein ezrin and PIKE (PI 3-kinase enhancer) GTPase, etc.
  • This finding demonstrates a negative feed-back loop from merlin/PIKE-L/PI 3-kinase to Akt in tumors- The proliferation repressive activity of merlin is also partially regulated by S518 phosphorylation- Thus, Akt-mediated merlin T230/S315 phosphorylation, combined with S518 phosphorylation by PAK and PKA, provides new insight into abrogating merlin function in the absence of merlin mutational inactivation.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Hum Mol Genet. 1998 Mar;7(3):335-45 [9466988.001]
  • [Cites] J Neurosci Res. 1998 Feb 1;51(3):403-15 [9486775.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):354-9 [9537418.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8447-54 [15378014.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5 [15598747.001]
  • [Cites] Oncogene. 2006 Sep 28;25(44):5960-8 [16652148.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1199-207 [17891137.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1699-712 [10669747.001]
  • [Cites] J Neurosci Res. 2000 Nov 15;62(4):491-502 [11070492.001]
  • [Cites] Cell. 2000 Dec 8;103(6):919-30 [11136977.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Hum Mol Genet. 2002 Dec 1;11(25):3167-78 [12444101.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):580-7 [14724586.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18559-66 [14981079.001]
  • [Cites] Adv Neurol. 1981;29:57-65 [6798843.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • (PMID = 19262146.001).
  • [ISSN] 1933-6926
  • [Journal-full-title] Cell adhesion & migration
  • [ISO-abbreviation] Cell Adh Migr
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA117872
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / GTPase-Activating Proteins; 0 / Neurofibromin 2; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / p21-Activated Kinases; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.1.- / AGAP2 protein, human; EC 3.6.1.- / GTP-Binding Proteins
  • [Number-of-references] 21
  • [Other-IDs] NLM/ PMC2634106
  •  go-up   go-down


74. Benesch M, Weber-Mzell D, Gerber NU, von Hoff K, Deinlein F, Krauss J, Warmuth-Metz M, Kortmann RD, Pietsch T, Driever PH, Quehenberger F, Urban C, Rutkowski S: Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. J Neurosurg Pediatr; 2010 Aug;6(2):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between 1991 and 2007, 29 patients (12 male and 17 female, median age at diagnosis 13.6 years) with primary spinal cord ependymoma (myxopapillary ependymoma WHO Grade I, II, and III tumors in 6, 17, and 6 patients, respectively) were identified.
  • Four patients had neurofibromatosis Type 2.
  • Seven patients (24.1%) developed progressive disease or relapse, 2 after gross-total resection (GTR) and 5 after incomplete resection or biopsy.
  • One patient with anaplastic ependymoma (WHO Grade III) died 65 months after diagnosis of disease progression.
  • [MeSH-minor] Adolescent. Austria. Biopsy. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Disability Evaluation. Disease Progression. Female. Follow-Up Studies. Germany. Humans. Male. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / drug therapy. Neurofibromatosis 2 / pathology. Neurofibromatosis 2 / radiotherapy. Neurofibromatosis 2 / surgery. Postoperative Complications / diagnosis. Postoperative Complications / mortality. Prospective Studies. Radiotherapy, Adjuvant. Registries. Survival Rate

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672934.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Walcott BP, Sivarajan G, Bashinskaya B, Anderson DE, Leonetti JP, Origitano TC: Sporadic unilateral vestibular schwannoma in the pediatric population. Clinical article. J Neurosurg Pediatr; 2009 Aug;4(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic unilateral vestibular schwannoma in the pediatric population. Clinical article.
  • OBJECT: Vestibular schwannomas (VSs) are rare in the pediatric population.
  • Most often, these lesions manifest as a bilateral disease process in the setting of neurofibromatosis Type 2.
  • Clinical outcomes were reviewed with emphasis on facial nerve function and follow-up for signs and symptoms of a heritable disorder.
  • The average tumor size was 4.57 cm, with an average duration of symptoms prior to definitive diagnosis of 31.2 months.
  • At a follow-up average of 6.3 years (range 1-12 years), 100% of patients demonstrated good facial function (House-Brackmann Grade I or II).
  • No patient in this cohort demonstrated symptoms, objective signs, or genetic analysis indicating the presence of neurofibromatosis Type 2.
  • CONCLUSIONS: Diagnosis and management of sporadic, unilateral VSs in children is complicated by clinical presentations and surgical challenges unique from their adult counterparts.
  • [MeSH-major] Facial Nerve / physiopathology. Neuroma, Acoustic / surgery
  • [MeSH-minor] Adolescent. Child. Cohort Studies. Ear, Inner. Female. Humans. Male. Neurofibromatosis 2 / pathology. Recovery of Function. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645545.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Pitchford CW, Schwartz HS, Atkinson JB, Cates JM: Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome. Am J Surg Pathol; 2006 Dec;30(12):1624-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue perineurioma in a patient with neurofibromatosis type 2: a tumor not previously associated with the NF2 syndrome.
  • Neoplasms that commonly affect patients with neurofibromatosis type 2 (NF2) include schwannomas, meningiomas, astrocytomas, ependymomas, and neurofibromas.
  • As in both NF2-associated and sporadic cases of schwannoma and meningioma, perineuriomas often harbor mutations or deletions of the NF2 gene.
  • However, perineuriomas have not previously been reported in the clinical setting of NF2.
  • A 30-year-old man with a history of bilateral vestibular schwannomas, a parasagittal meningioma, an intraspinal ependymoma, and multiple other neoplasms involving both cranial and peripheral nerves (thereby fulfilling the diagnostic criteria for NF2) presented with an enlarging thigh mass.
  • The diagnosis of cellular soft tissue perineurioma was confirmed by both immunohistochemical and ultrastructural analysis.
  • This case represents the first report of a soft tissue perineurioma arising in the setting of NF2.
  • [MeSH-major] Nerve Sheath Neoplasms / complications. Neurofibromatosis 2 / complications. Soft Tissue Neoplasms / complications
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cytoplasm / ultrastructure. Diagnosis, Differential. Humans. Male. Neoplasms, Multiple Primary. Peripheral Nervous System Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17122521.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Skarzynski H, Lorens A, Kochanek K, Mrowka M, Behr R: Bilateral auditory brainstem implantation in a patient with neurofibromatosis type II. Cochlear Implants Int; 2010 Jun;11 Suppl 1:88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral auditory brainstem implantation in a patient with neurofibromatosis type II.
  • [MeSH-major] Auditory Brain Stem Implantation / methods. Neurofibromatosis 2 / surgery. Neuroma, Acoustic / surgery. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21756589.001).
  • [ISSN] 1754-7628
  • [Journal-full-title] Cochlear implants international
  • [ISO-abbreviation] Cochlear Implants Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Scoles DR, Yong WH, Qin Y, Wawrowsky K, Pulst SM: Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c). Hum Mol Genet; 2006 Apr 1;15(7):1059-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis 2 (NF2) tumor suppressor protein, schwannomin or merlin, is commonly lost upon NF2 gene mutation in benign human brain tumors.
  • Consequently, eIF3c appears to be involved in NF2 pathogenesis and deserves to be investigated as a prognostic marker for NF2 and target for treatment of NF2 patient tumors.
  • [MeSH-minor] Adult. Cell Line, Transformed. Cell Proliferation. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunoprecipitation. Meningioma / metabolism. Meningioma / pathology. Models, Biological. Neurofibromatoses / metabolism. Protein Structure, Tertiary. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497727.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / KO8NS001428; United States / NINDS NIH HHS / NS / R01NS037883
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Eukaryotic Initiation Factor-3; 0 / Neurofibromin 2; 0 / Recombinant Proteins
  •  go-up   go-down


79. Chan AW, Black P, Ojemann RG, Barker FG 2nd, Kooy HM, Lopes VV, McKenna MJ, Shrieve DC, Martuza RL, Loeffler JS: Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery; 2005 Jul;57(1):60-70; discussion 60-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity.
  • OBJECTIVE: To determine the outcome and toxicity in patients with vestibular schwannomas treated with conventionally fractionated stereotactic radiotherapy (SRT) and to identify prognostic factors that are predictive of outcome.
  • METHODS: Between 1992 and 2001, 70 patients with vestibular schwannomas were treated with linear accelerator-based SRT in our institutions.
  • Eleven patients had neurofibromatosis Type II (NF2).
  • There was no difference in tumor control and cranial nerve function preservation rates seen in NF2 patients compared with non-NF2 patients.
  • [MeSH-major] Dose Fractionation. Neuroma, Acoustic / surgery. Radiosurgery / methods. Stereotaxic Techniques. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987541.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. An JH, Seong J, Oh H, Kim W, Han KH, Paik YH: [Protein expression profiles in a rat cirrhotic model induced by thioacetamide]. Korean J Hepatol; 2006 Mar;12(1):93-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: The reactive oxygen species from thioacetamide (TAA) induces rat liver cirrhosis that resembles the human disease, and it can serve as a suitable animal model for studying human liver cirrhosis.
  • In contrast, the expression level of the proteins did not show a significant change at 9 weeks, but this increased to 3-fold at 30 weeks for carbonic anhydrase VII, ras related protein Rab 6, Annexin A2, neurofibromatosis type 2 and aldehyde dehydrogenase.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565610.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Proteins; 075T165X8M / Thioacetamide
  •  go-up   go-down


81. Beyer KS, Beauchamp RL, Lee MF, Gusella JF, Näär AM, Ramesh V: Mediator subunit MED28 (Magicin) is a repressor of smooth muscle cell differentiation. J Biol Chem; 2007 Nov 2;282(44):32152-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magicin, a protein that we isolated earlier as an interactor of the neurofibromatosis 2 protein merlin, was independently identified as MED28, a subunit of the mammalian Mediator complex.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848560.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS24279; United States / NINDS NIH HHS / NS / NS45776
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / MED28 protein, human; 0 / Mediator Complex
  •  go-up   go-down


82. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR: The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol; 2005 Mar;25(6):2384-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.
  • Inactivation of the NF2 tumor suppressor gene has been observed in certain benign and malignant tumors.
  • Recent studies have demonstrated that merlin, the product of the NF2 gene, is regulated by Rac/PAK signaling.
  • In this report, we show that adenovirus-mediated expression of merlin in NF2-deficient tumor cells inhibits cell proliferation and arrests cells at G1 phase, concomitant with decreased expression of cyclin D1, inhibition of CDK4 activity, and dephosphorylation of pRB.
  • RNA interference experiments showed that silencing of the endogenous NF2 gene results in upregulation of cyclin D1 and S-phase entry.
  • Furthermore, PAK1-stimulated cyclin D1 promoter activity was repressed by cotransfection of NF2, and PAK activity was inhibited by expression of merlin.
  • Interestingly, the S518A mutant form of merlin, which is refractory to phosphorylation by PAK, was more efficient than the wild-type protein in inhibiting cell cycle progression and in repressing cyclin D1 promoter activity.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25245-9 [10464245.001]
  • [Cites] J Med Genet. 2000 Dec;37(12):897-904 [11106352.001]
  • [Cites] Genes Dev. 2001 Apr 15;15(8):968-80 [11316791.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34728-37 [11457831.001]
  • [Cites] Dev Cell. 2001 Jul;1(1):63-72 [11703924.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):69-76 [11773000.001]
  • [Cites] J Biol Chem. 2002 Jan 11;277(2):883-6 [11719502.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1150-7 [11809806.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10394-9 [11782491.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6023-33 [12167697.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Sep 6;296(5):1295-302 [12207915.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1090-100 [12695331.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):841-9 [14580336.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):71-4 [14657670.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1422-8 [14530270.001]
  • [Cites] Cancer J. 2004 Jan-Feb;10(1):20-6 [15000491.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7598-611 [15314168.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23387-90 [8089100.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1227-31 [7882313.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2270-4 [7757975.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23589-97 [7559524.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8 [7479897.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1324-35 [9032259.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2505-9 [9395247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1589-99 [9647651.001]
  • [Cites] Int J Cancer. 1998 Aug 12;77(4):554-60 [9679758.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2195-209 [9811451.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):85-92 [10389885.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Mar;24(3):238-42 [10451704.001]
  • [Cites] Cell. 2000 Oct 13;103(2):227-38 [11057896.001]
  • (PMID = 15743831.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075503; United States / NCI NIH HHS / CA / R01 CA093596; United States / NCI NIH HHS / CA / R01 CA045745; United States / NCI NIH HHS / CA / R29 CA070896; United States / NCI NIH HHS / CA / R01 CA070896; United States / PHS HHS / / T32-16850; United States / NCI NIH HHS / CA / CA-45745; United States / NCI NIH HHS / CA / CA-75503; United States / NCI NIH HHS / CA / CA-93596; United States / NCI NIH HHS / CA / R01 CA086072; United States / NCI NIH HHS / CA / CA-86072; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / CA-70896; United States / NCI NIH HHS / CA / CA-06927
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / RNA, Small Interfering; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / PAK1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / p21-Activated Kinases
  • [Other-IDs] NLM/ PMC1061616
  •  go-up   go-down


83. Gao X, Zhang R, Mao Y, Wang Y: Childhood and juvenile meningiomas. Childs Nerv Syst; 2009 Dec;25(12):1571-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Fifty-four meningioma cases below the age of 18 have been treated in Huashan Hospital in the last 15 years (from 1993 to 2008), their sex and age distribution, clinical manifestation, radiological finding, pathological subtype, treatment, and prognosis are retrospectively analyzed, and the results are compared with those reported in the literature.
  • Five patients in this series were associated with neurofibromatosis-2.
  • The most common radiological finding was homogeneous enhancement with contrast.
  • All of these patients were surgically treated; resection both in Simpson grades I and II could be achieved in 39 out of 54 patients.
  • Fibroblastic meningiomas were the most common pathological subtype, and malignant and atypical meningiomas (both of grades II and III according to WHO classification) accounted for 18.5% of the whole series.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / surgery. Meningioma / diagnosis. Meningioma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1998 May;38(1):41-9 [9540056.001]
  • [Cites] Br J Neurosurg. 1997 Dec;11(6):501-7 [11013621.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):477-85 [17182979.001]
  • [Cites] J Child Neurol. 2006 Jan;21(1):31-6 [16551450.001]
  • [Cites] Surg Neurol. 1984 Apr;21(4):319-22 [6701761.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):1-7 [15886506.001]
  • [Cites] Childs Nerv Syst. 1987;3(5):271-3 [3427568.001]
  • [Cites] J Clin Neurosci. 2004 Sep;11(7):715-8 [15337131.001]
  • [Cites] Pediatr Neurosurg. 1992;18(1):16-23 [1419837.001]
  • [Cites] Childs Nerv Syst. 1989 Apr;5(2):83-6 [2736555.001]
  • [Cites] J Neurooncol. 2000;46(3):205-13 [10902852.001]
  • [Cites] Mol Cell Endocrinol. 2006 Jul 25;254-255:1-7 [16824680.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):223-8 [7657383.001]
  • [Cites] Acta Neurochir (Wien). 1993;125(1-4):34-40 [8122553.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):179-82 [14758946.001]
  • [Cites] J Neurooncol. 2006 Mar;77(1):73-7 [16292489.001]
  • [Cites] Pediatr Neurosurg. 2008;44(1):43-8 [18097190.001]
  • [Cites] Cancer. 1976 Jun;37(6):2709-12 [949689.001]
  • [Cites] Crit Rev Neurosurg. 1999 May 25;9(3):180-188 [10369973.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Childs Nerv Syst. 2007 Feb;23(2):157-62 [16953459.001]
  • [Cites] Childs Nerv Syst. 2000 Jul;16(7):406-16 [10958549.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(5):485-93; discussion 493-4 [8800322.001]
  • [Cites] J Clin Neurosci. 2007 Aug;14(8):747-53 [17499508.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Childs Nerv Syst. 2001 Nov;17 (11):656-62 [11734983.001]
  • [Cites] Childs Brain. 1980;7(1):43-56 [7428495.001]
  • [Cites] Pathol Res Pract. 2008;204(5):305-14 [18374497.001]
  • [Cites] Neurosurgery. 1992 Aug;31(2):179-85 [1513424.001]
  • [Cites] Surg Neurol. 1987 Jan;27(1):64-8 [3787443.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1095-101 [8929501.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):140-5 [9490273.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):110-5 [17478763.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Pathol Res Pract. 2000;196(7):483-8 [10926326.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):112-7 [18230924.001]
  • [Cites] Childs Nerv Syst. 1996 Oct;12(10):582-8; discussion 589 [8934017.001]
  • [Cites] J Neurosurg. 1982 Mar;56(3):317-22 [7057228.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):136-40; discussion 140-1 [9457262.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):199-204 [11990306.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):447-53 [8113857.001]
  • [Cites] Neuroradiology. 1999 Jul;41(7):512-6 [10450846.001]
  • [Cites] Surg Neurol. 1996 Apr;45(4):328-35 [8607080.001]
  • (PMID = 19641924.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Larsson J, Ohishi M, Garrison B, Aspling M, Janzen V, Adams GB, Curto M, McClatchey AI, Schipani E, Scadden DT: Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture. Cell Stem Cell; 2008 Aug 7;3(2):221-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture.
  • We assessed whether the tumor suppressor and mediator of cell contact inhibition Nf2/merlin plays a role in governing the hematopoietic stem cell pool by stem cell-autonomous or niche-determined processes.
  • Hematopoietic stem cells in Nf2-deficient mice were increased in number and demonstrated a marked shift in location to the circulation.
  • Nf2/merlin is critical for maintaining normal structure and function of the hematopoietic stem cell niche.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682243.001).
  • [ISSN] 1875-9777
  • [Journal-full-title] Cell stem cell
  • [ISO-abbreviation] Cell Stem Cell
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL044851; United States / NCI NIH HHS / CA / CA113733; United States / NHLBI NIH HHS / HL / HL081030; United States / NHLBI NIH HHS / HL / HL44851; United States / NHLBI NIH HHS / HL / U54 HL081030
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurofibromin 2; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ NIHMS65568; NLM/ PMC4197168
  •  go-up   go-down


85. Tamura M, Carron R, Yomo S, Arkha Y, Muraciolle X, Porcheron D, Thomassin JM, Roche PH, Régis J: Hearing preservation after gamma knife radiosurgery for vestibular schwannomas presenting with high-level hearing. Neurosurgery; 2009 Feb;64(2):289-96; discussion 296
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hearing preservation after gamma knife radiosurgery for vestibular schwannomas presenting with high-level hearing.
  • OBJECTIVE: The aim of this study was to evaluate long-term hearing preservation after gamma knife radiosurgery (GKS) for vestibular schwannomas in patients with initially normal or subnormal hearing (Gardner-Robertson Class 1) and to determine the predictive factors for functional hearing preservation.
  • METHODS: Since July 1992, more than 2053 vestibular schwannomas have been treated by GKS and followed at the Timone University Hospital, Marseille.
  • A minimum of 3 years of follow-up (range, 3-11 years; median, 48 months) is available for 74 patients (without neurofibromatosis Type 2 or previous surgery) with Gardner-Robertson Class 1 hearing.
  • The number of tumors in Koos Stage I was 8, the average number in Stage II was 21, the average number in Stage III was 43, and the average number in Stage IV was 2.
  • CONCLUSION: This study shows that the probability of preserving functional hearing in the long term after GKS for patients presenting with unilateral vestibular schwannomas is very high.
  • [MeSH-major] Hearing Loss, Sensorineural / etiology. Hearing Loss, Sensorineural / prevention & control. Neuroma, Acoustic / complications. Neuroma, Acoustic / surgery. Quality of Life. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057423.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Chen DA: Acoustic neuroma in a private neurotology practice: trends in demographics and practice patterns. Laryngoscope; 2007 Nov;117(11):2003-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acoustic neuroma in a private neurotology practice: trends in demographics and practice patterns.
  • OBJECTIVES/HYPOTHESIS: To determine whether changes in demographics and management of patients with acoustic neuromas occurred between the years 1990 and 2005.
  • METHODS: Charts of all 614 patients with a diagnosis of acoustic neuroma, excluding neurofibromatosis-2, from 1990 through 2005 were reviewed.
  • Age at diagnosis, tumor size, hearing, and initial therapy (observation, stereotactic radiation, or surgical excision) were obtained.
  • RESULTS: Mean age at diagnosis increased slightly from the middle period (53.4 yr) to the most recent (56.9 yr) (P < or = .025).
  • CONCLUSION: : Patients with acoustic neuroma are presenting with increased age and smaller tumors compared with 16 years ago.
  • [MeSH-major] Neuroma, Acoustic / epidemiology. Neuroma, Acoustic / therapy. Practice Patterns, Physicians' / statistics & numerical data

  • Genetic Alliance. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17828042.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Pascual-Castroviejo I, Pascual-Pascual SI, Viaño J: [Neurofibromatosis type 2 (NF2). Study of 7 patients]. Neurologia; 2009 Sep;24(7):457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurofibromatosis type 2 (NF2). Study of 7 patients].
  • [Transliterated title] Neurofibromatosis tipo 2 (NF2). Estudio de 7 pacientes.
  • OBJECTIVE: The aim of this paper is to present the cases of 7 young children and young adult with type 2 neurofibromatosis (NF2).
  • In 5 patients, the symptoms because around the time of the diagnosis while 2 patients, who had no previous symptoms, were diagnosed by MRI after undergoing the test because a parent had been diagnosed of NF2 by MRI.
  • RESULTS: All 7 patients had bilateral vestibular schwannomas (VS) and only two had no associated intracranial and/or spinal tumors.
  • Deafness was the common sequel in all operated cases, associated with permanent bilateral facial paralysis in one and unilateral facial parenthesis in another.
  • CONCLUSION: A comparison of our series of NF1 and NF2 cases shows that the ratio of NF2:NF1 in childhood is approximately 1:100, and that the clinical features of NF2 are considerably more severe than in NF1.
  • [MeSH-major] Neurofibromatosis 2 / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Neurofibromatosis 1 / diagnosis. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / pathology. Young Adult

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921555.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


88. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES: Diagnostic criteria for schwannomatosis. Neurology; 2005 Jun 14;64(11):1838-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatoses are a diverse group of genetic conditions that share a predisposition to the development of tumors of the nerve sheath.
  • Schwannomatosis is a recently recognized third major form of neurofibromatosis (NF) that causes multiple schwannomas without vestibular tumors diagnostic of NF2.
  • Patients with schwannomatosis represent 2.4 to 5% of all patients requiring schwannoma resection and approximately one third of patients with schwannomatosis have anatomically localized disease with tumors limited to a single limb or segment of spine.
  • Epidemiologic studies suggest that schwannomatosis is as common as NF2, but that familial occurrence is inexplicably rare.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurofibromatosis 2 / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Neuroma, Acoustic / diagnosis

  • Genetic Alliance. consumer health - Schwannomatosis.
  • Genetics Home Reference. consumer health - schwannomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955931.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


89. Wei T, Zhu W, Zhang X, Li YF, Xiao H: Molecular design of 1,2,4,5-tetrazine-based high-energy density materials. J Phys Chem A; 2009 Aug 20;113(33):9404-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An analysis of the bond dissociation energies for the weakest bonds indicates that substitutions of the -N3, -NH2, -CN, -OH, or -Cl group are favorable for enhancing the thermal stability of 1,2,4,5-tetrazine, but the -NHNH2, -NHNO2, -NO2, -NF2, or -COOH group produces opposite effects.
  • The calculated detonation velocities and pressures indicate that the -NF2 or -NO2 group is very helpful for enhancing the detonation performance for the derivatives, but the case is quite the contrary for the -CN, -NH2, or -OH group.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642635.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterocyclic Compounds, 1-Ring; 0 / Tetrazoles
  •  go-up   go-down


90. Pérez-Grau M, Miró N, Prades J, Vergés J, Lareo S, Roca-Ribas F: [Neurofibromatosis type 2]. Acta Otorrinolaringol Esp; 2010 Jul-Aug;61(4):306-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neurofibromatosis type 2].
  • [Transliterated title] Neurofibromatosis tipo 2.
  • Type 2 neurofibromatosis (NF2) is an invalidating, inherited, dominant, autosomal disease.
  • It is commonly confused with type 1 neurofibromatosis, although the two disorders are different.
  • All subjects who inherit a mutated NF2 gene will develop the disease, which is characterised by the growth of schwannomas, generally affecting the vestibular nerve bilaterally, as well as meningiomas and other benign central nervous system tumours, before their third decade of life.
  • It is currently possible to identify the NF2 mutation in most affected families.
  • Up to about 20% of NF2 patients with no family history, apparently sporadic cases, are actually individuals with mosaicism for this mutation.
  • Small vestibular schwannomas can often be completely resected with preservation of both hearing and facial function.
  • In case of large tumours it is possible to place a cochlear or brain stem implant during the schwannoma surgery.
  • Age at diagnosis, the presence of intracranial meningiomas, and whether the patient was treated at a specialty centre or not, have been cited as the strongest prognostic factors.
  • [MeSH-major] Neurofibromatosis 2

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 20138250.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


91. Murovic JA, Kim DH, Kline DG: Neurofibromatosis-associated nerve sheath tumors. Case report and review of the literature. Neurosurg Focus; 2006;20(1):E1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis-associated nerve sheath tumors. Case report and review of the literature.
  • In this paper the authors describe a patient with neurofibromatosis Type 1 (NF1) who presented with sequelae of this disease.
  • They also review the current literature on NF1 and NF2 published between 2001 and 2005.
  • Neurofibromatosis Type 1 appears in approximately one in 2500 to 4000 births, is caused by a defect on 17q11.2, and results in neurofibromin inactivation.
  • The authors reviewed the current literature with regard to the following aspects of this disease:.
  • Neurofibromatosis Type 2 occurs much less frequently than NF1, that is, in one in 33,000 births.
  • Mutations in NF2 occur on 22q12 and result in inactivation of the tumor suppressor merlin.
  • The following data on this disease are presented:.
  • 1) diagnostic criteria for NF2;.
  • 2) criteria for other NF2 manifestations;.
  • 3) malignant PNSTs in patients with NF2;.
  • 4) examination protocol for the patient with NF2 who has an NST; and 5) imaging findings in patients with NF2.
  • It is important that neurosurgeons be aware of the sequelae of NF1 and NF2, because they may be called on to treat these conditions.
  • [MeSH-major] Nervous System Neoplasms / complications. Neurofibromatoses / complications

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459989.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


92. Samii M, Gerganov V, Samii A: Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results. Prog Neurol Surg; 2008;21:169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results.
  • AIM: To analyze the senior author's experience and strategy of treatment of patients with neurofibromatosis type 2 (NF2), with particular emphasis on vestibular schwannoma (VS) surgery.
  • MATERIALS AND METHODS: Over a period of more than 35 years, the senior author (M.S.) has operated on more than 165 patients with NF2.
  • Bilateral hearing after surgery was preserved in 23% of the patients.
  • CONCLUSIONS: The goal of VS surgery in patients with NF2 should be complete removal but not at the expense of functional impairment.
  • [MeSH-major] Microsurgery. Neurofibromatosis 2 / pathology. Neurofibromatosis 2 / surgery

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810216.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


93. Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A: Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet; 2007 Apr;71(4):354-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?
  • Early onset of vestibular schwannoma (VS) is associated with the inherited condition neurofibromatosis type 2 (NF2).
  • However, the majority of NF2 presents bilaterally and the proportion of early-onset apparent sporadic unilateral VS because of NF2 remains to be determined.
  • We have determined the risk by studying NF2 risk in a population-based set of VS, looking at the mode of presentation in a large NF2 data set and the outcome of NF2 mutation analysis in 148 sporadic unilateral vs. The risk of NF2 in an apparently sporadic case of unilateral VS is small apart from in the very youngest age group (<20 years).
  • NF2 germ line mutation testing is unlikely to reveal a mutation except <20 years as a result of the low risk and high rates of mosaicism.
  • Germ line mutation testing is probably only justified in sporadic unilateral VS <20 years unless other features of NF2 are present.
  • [MeSH-major] Genes, Neurofibromatosis 2. Mutation. Neuroma, Acoustic / genetics
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Child. DNA Mutational Analysis. England. Genetic Testing. Germ-Line Mutation. Humans. Middle Aged. Mosaicism. Neurofibromatosis 2 / complications. Neurofibromatosis 2 / genetics. Risk Factors

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470137.001).
  • [ISSN] 0009-9163
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


94. Martinez-Glez V, Franco-Hernandez C, Alvarez L, De Campos JM, Isla A, Vaquero J, Lassaletta L, Casartelli C, Rey JA: Meningiomas and schwannomas: molecular subgroup classification found by expression arrays. Int J Oncol; 2009 Feb;34(2):493-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As the molecular pathogenesis of meningiomas and schwannomas, characterized by NF2 gene alterations, remains unclear and suitable molecular targets need to be identified, we used low density cDNA microarrays to establish expression patterns of 96 cancer-related genes on 23 schwannomas, 42 meningiomas and 3 normal cerebral meninges.
  • We also performed a mutational analysis of the NF2 gene (PCR, dHPLC, Sequencing and MLPA), a search for 22q LOH and an analysis of gene silencing by promoter hypermethylation (MS-MLPA).
  • Results showed a high frequency of NF2 gene mutations (40%), increased 22q LOH as aggressiveness increased, frequent losses and gains by MLPA in benign meningiomas, and gene expression silencing by hypermethylation.
  • [MeSH-minor] Adult. Aged. DNA, Complementary / genetics. DNA, Neoplasm / genetics. Female. Gene Deletion. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Repeats / genetics. Middle Aged. Neurofibromatosis 2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148485.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Neoplasm
  •  go-up   go-down


95. Garrè ML, Capra V, Di Battista E, Giampietri L, Nozza P, Raso A, Pezzolo A, Rossi A, Milanaccio C, Pavanello M, Naselli A: Genetic abnormalities and CNS tumors: report of two cases of ependymoma associated with Klinefelter's Syndrome (KS). Childs Nerv Syst; 2007 Feb;23(2):219-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTS: Genetic syndromes associated with ependymoma are uncommon, with the exception of NF2.
  • MATERIALS AND METHODS: The first patient was diagnosed for KS during pregnancy; he also presented a thyroid agenesis and a deficit of methyltetrahydrofolate reductase (MTHFR); at 30 months of age he was operated on for a grade II ependymoma of IV ventricle; after a multiple-stage surgery, he underwent oral chemotherapy and stereotactic radiotherapy, but after 15 months he presented a local recurrence and died.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Klinefelter Syndrome / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / deficiency

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Klinefelter's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1997 Jan;28(1):59-61 [8950338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7825-9 [1679237.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):724-7 [2994794.001]
  • [Cites] Pediatr Hematol Oncol. 2004 Oct-Nov;21(7):621-6 [15626018.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):416-20 [7841064.001]
  • [Cites] Ann Hum Genet. 2001 Mar;65(Pt 2):177-88 [11427177.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4293-7 [9494523.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):553-8; discussion 559 [14670679.001]
  • [Cites] Intern Med. 1996 Apr;35(4):285-9 [8739783.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):9-13 [12547150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6 [15668471.001]
  • [Cites] Int J Urol. 1999 Mar;6(3):158-61 [10226829.001]
  • (PMID = 17058088.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


96. Javalkar VK, Pigott T, Pal P, Findlay G: Multiple schwannomas: report of two cases. Eur Spine J; 2007 Dec;16 Suppl 3:287-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper authors present two cases of multiple schwannomas without the features of neurofibromatosis (NF).
  • There was no family history of neurofibromatosis.
  • The two patients had contrast enhanced MRI, which was negative for vestibular schwannomas.
  • Molecular genetic analysis in case 1 demonstrated two distinct mutations of the NF2 gene in two different schwannomas, with concomitant loss of heterozygosity in both tumours.
  • In contrast peripheral blood lymphocytes did not reveal mutations of NF2.
  • [MeSH-major] Neurilemmoma / diagnosis. Polyradiculopathy / etiology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Back Pain / etiology. Back Pain / pathology. Back Pain / physiopathology. Diagnosis, Differential. Genetic Markers. Humans. Magnetic Resonance Imaging. Male. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / genetics. Neurofibromin 2 / genetics. Neurosurgical Procedures. Retrospective Studies. Spinal Canal / pathology. Spinal Canal / physiopathology. Spinal Canal / surgery. Spinal Cord / pathology. Spinal Cord / physiopathology. Spinal Nerve Roots / injuries. Spinal Nerve Roots / pathology. Spinal Nerve Roots / physiopathology. Subarachnoid Space / pathology. Subarachnoid Space / physiopathology. Subarachnoid Space / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):747-55 [11257108.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):92-6 [8355853.001]
  • [Cites] Neurology. 2003 Jun 24;60(12):1968-74 [12821741.001]
  • [Cites] Surg Neurol. 2004 Oct;62(4):353-61; discussion 361 [15451291.001]
  • [Cites] N Engl J Med. 1981 Dec 31;305(27):1617-27 [6796886.001]
  • [Cites] Am J Surg Pathol. 1981 Dec;5(8):733-44 [7337161.001]
  • [Cites] J Hand Surg Am. 1987 Mar;12(2):307-11 [3559095.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] Spine (Phila Pa 1976). 1993 Dec;18(16):2556-9 [8303467.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):362-73 [8057143.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Neurology. 1996 Apr;46(4):1072-9 [8780094.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):361-6 [9120449.001]
  • [Cites] Neurobiol Dis. 1997;3(4):247-61 [9173923.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Dermatology. 1997;195(3):228-31 [9407167.001]
  • [Cites] Am J Hum Genet. 1997 Dec;61(6):1293-302 [9399891.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):36-41 [9647170.001]
  • [Cites] Clin Orthop Relat Res. 1998 Dec;(357):171-5 [9917714.001]
  • [Cites] Childs Nerv Syst. 1999 Jul;15(6-7):295-308 [10461778.001]
  • [Cites] Neurology. 2005 Jun 14;64(11):1838-45 [15955931.001]
  • [Cites] Neurology. 2006 Mar 14;66(5):730-2 [16534111.001]
  • [Cites] Arch Dermatol. 1989 Mar;125(3):390-3 [2493772.001]
  • [Cites] Ann Intern Med. 1990 Jul 1;113(1):39-52 [2112353.001]
  • [Cites] J Neurosurg. 1991 Feb;74(2):248-53 [1846409.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):331-8 [1413494.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Cell. 1993 Mar 12;72(5):791-800 [8453669.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):515-21 [8379998.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):109-13 [11310197.001]
  • (PMID = 17216226.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Neurofibromin 2
  • [Other-IDs] NLM/ PMC2148085
  •  go-up   go-down


97. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, Yatabe Y, Hasegawa Y, Shimokata K, Horio Y, Hida T, Sekido Y: YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis; 2008 Nov;29(11):2139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the involvement of YAP1 in MPM proliferation, as well as its functional and physical interaction with Merlin encoded by the neurofibromatosis type 2 (NF2) tumor suppressor gene, which is frequently mutated in MPMs.
  • YAP1-RNA interference suppressed growth of a mesothelioma cell line NCI-H290 with NF2 homozygous deletion, probably through cell-cycle arrest and apoptosis induction, whereas YAP1 transfection promoted the growth of MeT-5A, an immortalized mesothelial cell line.
  • We also found that the introduction of NF2 into NCI-H290 induced phosphorylation at serine 127 of YAP1, which was accompanied by reduction of nuclear localization of YAP1, whereas nuclear localization of a YAP1 S 127A mutant was not affected.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18725387.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BIRC2 protein, human; 0 / DNA Primers; 0 / Inhibitor of Apoptosis Proteins; 0 / Neurofibromin 2; 0 / Phosphoproteins; 0 / YAP1 (Yes-associated) protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


98. Neff BA, Welling DB: Current concepts in the evaluation and treatment of neurofibromatosis type II. Otolaryngol Clin North Am; 2005 Aug;38(4):671-84, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the evaluation and treatment of neurofibromatosis type II.
  • This article presents the current diagnostic and treatment options for the hereditary disease neurofibromatosis type II, reviews clinical presentation and diagnosis, highlights indications for and methods of clinical and genetic screening, discusses treatment approaches for surgery and stereotactic radiation, and summarizes potential future therapeutic avenues.
  • [MeSH-major] Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005725.001).
  • [ISSN] 0030-6665
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


99. Lee HH, Lian SL, Huang CJ, Huang MY: Tomotherapy for neurofibromatosis Type 2: case report and review of the literature. Br J Radiol; 2010 Apr;83(988):e74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tomotherapy for neurofibromatosis Type 2: case report and review of the literature.
  • Neurofibromatosis 2 (NF2) results in multiple central nervous system tumours.
  • In this case report, the patient has one vestibular schwannoma, one trigeminal schwannoma and two meningiomas developed before the age of 30.
  • This is the first reported case of clinical experience with tomotherapy in the management of NF2.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Meningioma / radiotherapy. Neurofibromatosis 2 / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adult. Dose Fractionation. Female. Humans. Magnetic Resonance Imaging. Neurilemmoma / diagnosis. Neurilemmoma / radiotherapy. Neuroma, Acoustic / diagnosis. Neuroma, Acoustic / radiotherapy. Tomography, X-Ray Computed. Treatment Outcome. Trigeminal Nerve Diseases / diagnosis. Trigeminal Nerve Diseases / radiotherapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pediatr Adolesc Med. 2000 Sep;154(9):961-2 [10980805.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12):655-62 [19107346.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1265-78 [11483338.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Nov;127(11):1385-9 [11701080.001]
  • [Cites] Yonsei Med J. 2002 Feb;43(1):109-13 [11854940.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1390-6 [12873685.001]
  • [Cites] Arch Otolaryngol. 1980 Dec;106(12):729-33 [7436847.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Sep;116(9):1023-5 [1696486.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):147-52 [1572811.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] J Neurosurg. 1994 Mar;80(3):541-7 [8113868.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Aug 1;36(1):141-5 [8823269.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1229-33 [8906059.001]
  • [Cites] Brain Pathol. 1997 Apr;7(2):823-36 [9161732.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):226-9 [9167741.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):50-8; discussion 58-60 [9218295.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1119-20; author reply 1120-1 [10206835.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):75-81 [16111574.001]
  • [Cites] Neurology. 2006 Mar 14;66(5):730-2 [16534111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1341-7 [16464537.001]
  • [Cites] Radiat Oncol. 2006;1:26 [16887031.001]
  • [Cites] Technol Cancer Res Treat. 2008 Dec;7(6):417-24 [19044320.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):747-55 [11257108.001]
  • (PMID = 20335436.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC3473451
  •  go-up   go-down


100. Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res; 2009 Aug 15;15(16):5032-5039
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
  • PURPOSE: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves.
  • Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2.
  • The lack of effective treatments for NF2 marks an unmet medical need.
  • Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials.
  • RESULTS: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials.
  • Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2.
  • CONCLUSIONS: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials.
  • The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.
  • [MeSH-major] Clinical Trials as Topic / methods. Consensus. Health Planning Guidelines. Neurofibromatosis 2 / therapy

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 2.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2002 Mar;20(3):475-82 [11836557.001]
  • [Cites] Curr Biol. 2006 Apr 4;16(7):702-9 [16581517.001]
  • [Cites] J Med Genet. 2007 Jul;44(7):424-8 [17307835.001]
  • [Cites] Hum Gene Ther. 2006 Jan;17(1):20-30 [16409122.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] J Med Genet. 2008 Jun;45(6):332-9 [18285426.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1069-72 [17545869.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):27-36 [16341207.001]
  • [Cites] Genes Dev. 2005 Oct 1;19(19):2265-77 [16204178.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):501-9 [12407444.001]
  • [Cites] Oncogene. 2009 Feb 12;28(6):854-65 [19029950.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):978-86 [10215625.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] Otol Neurotol. 2005 Jul;26(4):733-40 [16015177.001]
  • [Cites] Otol Neurotol. 2008 Jan;29(1):58-68 [18199958.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):994-1003 [11589430.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1063-71 [12066908.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Neurology. 2002 Dec 10;59(11):1759-65 [12473765.001]
  • [Cites] Am J Otol. 1998 Sep;19(5):638-43 [9752973.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] Neurosurgery. 2008 Jun;62(6):1314-9; discussion 1319-20 [18824998.001]
  • [Cites] Neurology. 2007 Feb 27;68(9):643-7 [17215493.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):577-81 [17726450.001]
  • [Cites] Stat Med. 1999 Aug 15;18(15):1905-42 [10532877.001]
  • [Cites] Am J Hum Genet. 2007 Apr;80(4):805-10 [17357086.001]
  • [Cites] Neurology. 2000 Jan 11;54(1):71-6 [10636128.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Cell Biol. 2007 Jun 4;177(5):893-903 [17548515.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 19671848.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDCD NIH HHS / DC / K08 DC009288
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS707923; NLM/ PMC4513640
  •  go-up   go-down






Advertisement